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Blood Levels of Protein C Among Intensive Care Unit Patients 





Background: Intensive care unit (ICU) is one of the largest, most expensive, 
and complex components of health care. However, assessment of  protein     
C (PC) and C- reactive protein (CRP) concentrations in ICU patients may help 
in identifying high risk groups and potential therapeutic targets. 
Objective: To estimate the PC levels and CRP among ICU patients and their 
relations to ICU outcome.  
Methods:  This observational cross sectional study, in Al-Shifa hospital ICU, 
included 85  patients, and 85 healthy controls. Plasma PC concentrations, and 
CRP levels were measured. Kidney and liver dysfunctions were assessed 
biochemically, in addition, coagulation tests were performed. 
Results: PC levels were below the lower limit of normal in 65.9% of patients 
(n=56) at admission, irrespective of the presence primary diagnosis and sex. 
PC levels were lower in non survivors (n=17 ; 20%) than in survivors.  There 
was significant correlation between PC levels and ICU outcome  (P=0.001). 
Patients with high CRP levels upon ICU admission had higher mortality rates 
than patients with normal levels. There was no significant correlation between 
CRP levels and ICU outcome  (P=0.856). 
Conclusion: 
PC concentrations are generally low in ICU patients. PC levels were also 
associated with organ dysfunction/failure and were independently associated 
with a higher risk of ICU mortality. CRP levels are considered as a good early 
marker of morbidity and mortality in these patients. In addition, CRP 
concentrations may be a valuable addition to predict the risk of death.  
 





،  العناية املركزة يف قطاع غزة وحدةمستوى الربوتني سي لدى مرضى
 فلسطني
  اخلالصة
واحدة من أكبر الوحدات الصحية  تكلفة حيث نشتمل على ) آي سي يو(وحدة العناية المركزة  تعتبر :مقدمة
"  سي"وكذلك البروتين  النشط ) بي سي(ان تقدير تركيز البروتين سي . مكونات معقدة من الرعاية الصحية
في مجموعة مرضى وحدة العناية المركزة  قد يساعد في تحديد  المجموعات التي تتعرض الخطار عالية 
  .ير الجدوى العالجية لهذه المجموعة بمستحضر البروتين سي وأهداف االمكانية العالجيةومن ثم تقد
بين مرضى العناية المركزة وعالقة تلك " سي" تقدير مستويات البروتين سي وكذلك البروتين  النشط :الهدف
  . المستويات بمصير المرضى في وحدة العناية المركزة
 حالة تم 85يض من وحدة العناية المركزة في مستشفى الشفاء و مر85هذه الدراسة تضمن : الطريقة
  .اختيارهم كعينة ضابطة
في دماء هؤالء المرضى كما تم عمل الفحوصات " سي"تم قياس كل من مستوى البروتين سي والبروتين النشط
  . التجلطالدالة على فشل الكية والكبد بالطرق الكيمياوية  باالضافة  الى االختبارات الخاصة بعوامل
 من (n=56)% 65.9مستويات البروتين سي أقل من الحد االدنى للوضع الطبيعي في  لقد كانت: النتائج
  .التشخيص والجنس بصرف النظر عن،المرضى اللذين تم دخولهم الى وحدة العناية المركزة 
لمرضى الباقون  بالمقارنة مع ا(n=17, 20%)مستويات البروتين سي كانت أقل في المرضى الذين توفوا 
وقد وجد ارتباط بين مستويات البروتين سي ومصير المريض في وحدة العناية المركزة . على قيد الحياة
(P=0.001)    
أعلى من المعدل الطبيعي عند دخولهم " سي" وقد لوحظ أن المرضى الذين لديهم مستوى البروتين النشط 
بر من المرضى الذين كان عندهم مستوى البروتين النشط وحدة العناية المركزة قد تعرضوا للوفاة بنسبة أك
  .طبيعي عند دخولهم الى وحدة العناية المركزة" سي"
ومصير المرضى في وحدة العناية المركزة " سي"ال يوجد هناك  ارتباط بين مستوى البروتين النشط
(P=0.856)  
كما لوحظ ارتفاع مستوى .ة المركزة لقد لوحظ انخفاض  مستوى البروتين سي لدى مرضى العناي:االستنتاج
لدى هؤالء المرضى لذا يعتبر األخير عامال مبكرا لتحديد الحاالت المرضية وحاالت " سي"البروتين النشط 
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        Protein C (PC) is a vitamin K-dependent zymogen of serine protease that 
inhibits blood coagulation by the proteolytic inactivation of factors Va and VIIIa 
(1). Individuals affected with PC deficiency are at risk for arterial or venous 
thrombosis (2). The diagnosis of PC deficiency has been based on the 
laboratory assay of plasma PC antigen and activity levels (3).  
 
       Protein C deficiency has phenotypically been classified into two types, 
type I deficiency, the most common, is characterized by the parallel reduction 
of PC activity and antigen levels due to the reduced synthesis or stability of 
normally functioning molecules. In type II deficiency, PC activity is reduced to 
a greater extent than the antigen due to the synthesis of an abnormal PC 
molecule exhibiting a reduced specific activity (4). PC deficiencies are 
inherited as an autosomal dominant trait. The PC gene resides on 
chromosome 2 and comprises 9 exons (5). Researchers have found over 160 
different mutations of the protein C gene that lead to the absence, or a 
defective form, of PC (6). 
        
       Protein C is the zymogen of activated protein C (APC). PC is activated in 
vivo by the thrombin– thrombomodulin complex (7) and this activation is 
enhanced by the endothelial cell protein C receptor (EPCR) (8). Besides its 
well known anticoagulant activity, APC also has anti-inflammatory, anti-
apoptotic, and other cellular activities that are mediated by the binding of APC 
to EPCR and the subsequent cleavage of proteolytically activated receptor 1 
(PAR1) (9,10).  
        
       The PC system is an important regulator of hemostasis and also plays a 
crucial role during the systemic response to acute inflammatory challenge. 
The anticoagulant, AِPC, arises from activation of its zymogen, PC, through 
 2
catalysis with thrombin. The reaction is optimal when PC is bound to its EPCR 
and thrombin is present in complex with another cellular receptor, 
thrombomodulin (TM) (11,12). The resulting APC, along with calcium ions  
(Ca+2), phospholipids, and a cofactor, protein S, catalyzes inactivation of 2 
potent pro-coagulant cofactors, FVa and FVIIIa (13). This leads to APC-
mediated attenuation of thrombin generation and consequently an inhibition of 
coagulation and inflammation (14,15). APC also stimulates fibrinolysis by 
directly inactivating plasminogen activator inhibitor-1 (PAI-1) (16). During 
acute inflammation, plasma APC levels are diminished. Cytokines such as 
Interleukin-1β (IL-1β) and Tumor necrosis factor-α (TNF-α), as well as 
endotoxin, can attenuate TM and EPCR expression (17). This further reduces 
the ability of endothelial cells (ECs) to generate APC. Studies have shown 
that patients with severe sepsis also have a rapid decrease in APC production 
(18) and APC levels are strongly correlated with sepsis prognosis (19).  
 
       Abnormalities of APC or its activation may be pathogenically associated 
with diseases such as disseminated intravascular coagulation, deep vein 
thrombosis, and purpura fulminans (20). Alternative uses of APC have been 
studied in murine models of stroke and other coagulopathies (21,22). Several 
APC inhibitors have been identified in plasma, including the heparin-
dependent serpin protein C inhibitor (PCI), alpha 1-antitrypsin, alpha 2-
antiplasmin, and alpha 2-macroglobulin (23).  
 
       Administration of recombinant human aPC (rhaPC) led to reduced 
mortality in a subset of patients with severe sepsis and a deficiency of 
endogenous PC exacerbated the endotoxic (24) and septic (25) responses in 
mice. A variety of coagulation, inflammation, cell migratory, and hemodynamic 
factors (26) have been offered as predictors of outcome and targets of therapy 
in patients. 
        Activation of inflammatory pathways can, however, occur in a variety of 
clinical conditions in the intensive care unit (ICU), including after surgical 
interventions and traumatic injury. Reported considerable alterations in the 
hemostatic network in patients with severe trauma and those admitted to the 
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ICU after neurosurgical procedures. PC concentrations were more markedly 
decreased in patients with sepsis compared to those with severe trauma and 
neurosurgery (27). Characterizing the evolution of protein C concentrations 
and their possible relationship to morbidity and mortality may help in 
identifying high-risk groups and potential  therapeutic targets. 
       C-reactive protein (CRP) is an acute-phase protein, the blood levels of 
which increase rapidly in response to infection, trauma, ischemia, burns, and 
other inflammatory conditions. Although used frequently in the ICU as a 

























1.2 Objectives  
 
General objective  
       Estimation of  protein C levels and their relation to the presence of organ 
dysfunction/failure, and the outcome of ICU patients in Gaza Strip.  
 
Specific objectives  
 
1- To assess the correlation between low levels of protein C in  patients     
admitted to the ICU and the risk of organ dysfunction/failure and/or death.          
2-To investigate the relationship between protein C levels and outcome of                                             
patients admitted to ICU. 
3-To estimate the level of C-reactive protein in these patients and find its                                                                                                                                                        
relation with protein C. 
4- To investigate the biochemical markers related to liver and kidney as well 
as coagulation parameters. 
5-To highlight a new  laboratory test (PC levels) which may help to  identify 
patients with severe sepsis and multi system organ failure . 
 
1.3 Significance  
       There is  a high mortality rate in the ICU. Patients admitted to the ICU 
suffer major health problems in Gaza strip as in many communities. No 
studies had been done in Gaza to determine the clinical role of protein C 
among ICU patients. Many studies over the world showed that low levels of  
protein C represents one of the markers which reflect the deteriorating 
condition of critically ill patients. This research may draw the attention of 
physicians for the importance of protein C in both morbidity and mortality and 
they probably will persuade health authorities to introduce recombinant  
human  activated protein C as an option in the treatment protocol of ICU 
patients.                                                                           





 iterature Review                               LChapter II                
 
2.1 Background 
        
       A key factor regulating the balance of endothelial and leukocyte function 
is APC (29). Low PC levels are predictive of early death during sepsis in both 
human (30) and rat model of polymicriobial sepsis (31). Sepsis is the prime 
factor contributing to death in the ICU, and it is the eleventh most common 
cause of death in America. Research in the past two decades suggests that 
the imbalance between pro- and anti-inflammatory reactions is the main 
mechanism of organ injury in septic patients. Sepsis was defined in 1992 by 
the Society of Critical Care Medicine (SCCM). "as infection-induced systemic 
inflammatory reaction syndrome (SIRS)". This suggests that sepsis cannot be 
more effectively managed only by adding anti-coagulation therapy. Recently 
the pathophysiology of sepsis was studied intensively, revealing a complex 
network of interactions between coagulation and inflammation (32). 
Coagulation is an important part of the innate immunity, and shares its 
biologic evolution with inflammation (33). Mononuclear and endothelial cells 
play vital role not only in inflammation but also in coagulation. When 
challenged by endotoxin, they not only produce inflammatory factors, but 
express tissue factors (TFs) and initiate the extrinsic coagulation pathway as 
well (34). APC, one of the most important endogenous inhibitors of 
coagulation, has recently been shown to exhibit anti-inflammatory activities. 
Clinical trial has shown that APC can down-regulate plasma IL-6 and D-dimer 
level in severe sepsis patients, lowering the mortality (35). APC can down-
regulate the TNF-α production on LPS (lipopolysaccharide) stimulated 
mononuclear cell through nuclear factor_κB (NF-κB ) activation pathway (36).  
 
2.2 Blood coagulation 
 
The classical model of blood coagulation consists of, a chain of cascade-like 
activations of proenzymes that occur in two parallel, and to some extent 
interacting, systems referred to as the intrinsic and extrinsic pathways. These 
two sequences of reactions converge in a common pathway that involves 
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activation of factor IX (FIX) and FX to FIXa and FXa, and terminates with the 













       Sepsis is widely recognized as a clinical syndrome, resulting from an 
overwhelming, systemic host response to infection (38). It is the most 
common cause of death among hospitalized patients in non cardiac intensive 
care units and has instigated a lot of preclinical and clinical research (39). In 
the last years, tremendous progress has been made in understanding the 
complex triad of infection, inflammation, and coagulation during sepsis. 
It is now well established that in sepsis, systemic inflammation invariably 
leads to activation of the coagulation system and inhibition of anticoagulant 
mechanisms and fibrinolysis. Activation of coagulation and subsequent fibrin 
deposition are essential parts of the host defense against infectious agents 
(40). In normal situations, the endothelium functions as an antithrombotic 
surface, preventing inappropriate activation of coagulation on the cell 
membrane (41). However, once in sepsis, the endothelium becomes 
activated; it transforms into a prothrombotic interface, which is critically 
involved in the detrimental cascade leading to multiple organ failure (42). 
tissue factor, thrombin, the PC pathway, activators and inhibitors of 
fibrinolysis, and protease-activated receptors  (PARs) have all been shown to 
play vital roles in the crosstalk between inflammation and coagulation in 


















Figure 2. 2. The complex path of sepsis (43). 










2.4 Protein C biochemistry 
 
2.4.1 Structural and functional aspects 
 
       Protein C is synthesized in the liver as a 461 amino acids long single 
chain precursor. Prior to secretion, it is processed into a disulfide-linked two 
chain polypeptide containing, one light (155 amino acids) and one heavy 
chain (262 amino acids). The molecular weight of the mature protein is 
approximately 62,000 daltons and its carbohydrate content about 23%. It 
circulates in human plasma at a concentration of 3-5µg/ml and its half-life is 6-
8 hours. PC is an inactive pro-enzyme or zymogen of a serine protease APC. 
From information based upon the PC gene structure and amino acid 
sequence homologies with other proteins, it is clear that PC contains several 
regions with discrete structural or functional properties (Figure 2.3) (44). 
 
 
Figure 2.3. Domain structure of human protein C. Symbols: Y = Gla-residues, Hya = erythro 
βhydroxy aspartic acid, O = catalytic residues,  ∆= N-linked glycosylation sites (44). 
Gla = γ - carboxyglutamate, EGF= epidermal growth factor. 
 
The amino terminal light chain consists of a Gla-domain, with nine glutamic 
acid residues that are γ - carboxylated in a vitamin K-dependent reaction in 
the liver. This region interacts with negatively charged phospholipid in the 
presence of Ca2+ and is a prerequisite for the anticoagulant function of APC. 
The Gla-domain is followed by two EGF-like domains, which appear to 
interact with protein S. Together with the Gla-domain these domains are also 
important for the binding of PC to the thrombin-thrombomodulin complex. The 
heavy chain contains the serine protease domain with the 'catalytic triad' 
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composed of histidine, aspartic acid and serine (located at position 211, 257 
and 360, respectively). These amino acid residues are situated relatively far 
apart from each other in the primary structure, but are in close proximity in the 
folded protein. APC cleaves substrates with arginine in the P1 position, 
whereas the amino acid composition in the P2 and P3 positions are more 




Figure 2.4. The cleavage-site composition of APC's natural 
substrates, factors Va and VIIIa (45). 
 
 
It is not known which structural features give APC its narrow specificity for 
factors Va and VIIIa although, it probably involves a secondary binding site 
located outside the catalytic center. Recent studies using synthetic peptides 
indicate that the amino acid residues 311- 325 and 390-404 in APC are 
important for its anticoagulant interaction with substrates (45). 
 
2.4.2 Protein C activation 
 
       Protein C must be transformed to an active serine protease to be 
physiologically functional. The activation of human PC occurs through the 
enzymatic removal of a small activation peptide from the aminoterminus of the 
heavy chain. In vivo, the activation is mediated by the thrombin-
thrombomodulin complex. In vitro, the activation can be achieved using 







        
       Activation of PC by thrombin alone is slow and has no physiological 
function. However, when thrombin binds to the integral membrane protein TM, 
present on the vascular endothelium, the result is a 20,000-fold increase in 
the rate by which thrombin activates PC. TM also removes the procoagulant 
properties of thrombin and accelerates the thrombin-antithrombin reaction by 
a glycosaminoglycan moiety, identified as chondroitin sulfate (47). Calcium is 
an important regulator that enhances PC activation by the thrombin-TM 
complex, but inhibits the activation by thrombin (48). The mature TM molecule 
consists of 557 amino acids residues arranged in a lectin-like domain, six 
EGF-like domains, a Ser/Thr-rich domain, a transmembrane domain, and a 
short cytoplasmic tail (Figure 2.5).  
 
Figure 2. 5. Domain structure of thrombomodulin (49). 
                                EGF= epidermal growth factor 
TM has a widespread distribution in the mammalian organism and with few 
exceptions, is expressed by endothelial cells of arteries, veins, capillaries, and 
lymphatic vessels. The highest concentration of TM is found in the capillaries, 
where the ratio of endothelial surface to the volume of circulating blood is 
high. Thrombin entering the microcirculation will therefore be extracted rapidly 
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by TM and PC will be activated. This is physiologically important as even 
small amounts of thrombin would generate enough fibrin to stop the blood flow 
in the microvasculature (49). 
 
2.4.4 APC cofactors 
       The molecular mechanisms involved in the PC anticoagulant system is 
highly complex and so far poorly understood. However, essential for the 
maximal catalytic efficiency of APC is probably the presence of helper 
proteins or cofactors, which promote the binding of APC to phospholipid on 
cellular surfaces and give support to the APC degradation of the membrane-
bound factors Va and VIIIa. Two cofactors are now associated with APC, one 
is the cofactor-function of factor V , the other is the established cofactor, 
protein S (50). 
 
2.4.5 APC inhibitors 
       APC is inhibited relatively slowly by at least three protease inhibitors in 
plasma, including PC inhibitor (also known as PAI-3),(51) trypsin inhibitor,(52) 
and α2-macroglobulin. Heparin stimulates only the activity of the PC inhibitor. 
The half-life of APC in the circulation is about 10-20 minutes (53). 
 
2.5 Clinical aspects 
 
2.5.1 Protein C deficiency 
       Venous thrombosis is a serious medical problem, which annually affects 1 
in 1000 people (54). The pathogenesis of the disease is very likely 
multifactoral, involving both circumstantial and genetic risk factors. The 
importance of identifying the underlying genetic cause has been obvious, as 
up to 40% of patients with thrombosis have positive family histories. The 
major hereditary disorders of the coagulation system known to predispose for 
venous thrombosis, include APC resistance and deficiencies of PC, protein S, 
and antithrombin. Together these defects may account for up to 60% of cases 
with familial thrombophilia or about 30% of unselected thrombosis patients 
(45). 
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2.5.2 Hereditary protein C deficiency 
       The relevance of evaluating PC levels in a patient's plasma became clear 
in 1981, when the first case of hereditary PC deficiency associated with 
thrombotic disease was reported by Griffin and his colleagues (55). Several 
studies have confirmed this initial report and it has been shown that 
individuals with an isolated PC deficiency may run a 6 to 9-fold increased risk 
for venous thrombosis (56). 
 
2.5.3 Acquired protein C deficiency 
       The PC level is influenced by various diseases and drugs. Acquired PC 
deficiency is often associated with disseminated intravascular coagulation 
(DIC), deep vein thrombosis, severe liver disease, sepsis, vitamin K 
deficiency, oral anticoagulant therapy and elective surgery. The PC activity 
level may in some cases indicate the severity of a disease and can be used 
as a prognostic parameter (57). 
 
2.5.4 Protein C levels 
       Hereditary PC deficiency is inherited as an autosomal dominant trait. 
Heterozygotes for PC deficiency have PC activity or antigen levels of 30 to 
70% of normal, whereas homozygotes (or compound heterozygotes) with a 
severe defect have levels below 1%. Homozygotes with a mild defect have 
also been reported with PC levels of 10-24% (58) .The normal range of PC in 
the adult is 70% to 130% of a normal plasma pool (defined as 100%)(59). 
 
2.5.5 Prevalence protein C 
       The prevalence of PC deficiency is 2-5% in patients with thromboembolic 
disease (60). Selected patient-groups with thrombosis occurring at a young 
age tend to have a higher prevalence (up to 10-15%). Extrapolation into the 
general population would give an estimate prevalence for symptomatic PC 
deficiency of one in 20,000 people. However, the identification of symptom-
free individuals with PC deficiency in large groups of healthy blood donors put 
the prevalence at between one in 200 and one in 500. The majority of these 
individuals did not present family histories of thrombosis. It remains to be 
established whether clinical phenotypes reflect different defects in the PC 
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gene or if additional risk factors, genetic or circumstantial, are required for 
expression of the symptomatic phenotype (61). 
 
2.5.6 Classification protein C 
       Two types of protein C deficiency states are recognized (Figure 2.6). 
 
 
Figure 2. 6. Classification of protein C deficiency and 
the criteria for laboratory assessment (62). 
 
1- In type I deficiency the plasma concentration of PC is reduced both in 
functional and immunological assays, reflecting a genetic defect causing a 
reduced biosynthesis of PC. 
 2-Type II deficiency is characterized by normal PC antigen levels, but with 
decreased functional activity. This type of defect reflects the synthesis of 
abnormal molecules with reduced function. Type I deficiency is the most 





2.5.7 Elevated protein C levels 
       Elevated PC levels have been reported in diabetic and nephrotic patients, 
during late pregnancy, and with oral contraceptives and anabolic steroids (58).  
 
2.6 Protein C assays 
 
       Protein C circulates in the blood in zymogen form (inactivated form) at a 
concentration of approximately 4 µg/ml. Currently, various methods, reagents 
and equipment exist to measure PC in the laboratory or even at the bedside in 
the ICU. In general, these methods can be subdivided into those that are 
based on measuring the functional activity of the protein (%) and antigenic 
methods, which measure the amount of protein available (µg/ml). The 
laboratory evaluation of PC is the only definitive way of diagnosing hereditary 
PC deficiency in thrombophilic patients. Various types of assays have been 
developed and some are available in commercial kit form. PC is measured 
using either a functional assay, that tries to evaluate the biological activity of 
PC, or an immunological assay, which determines the total amount of PC 
related material in plasma. Each assay has a number of pros and cons. 
However, for the routine screening of hereditary PC deficiency, a functional 
activity assay is generally recommended. This approach will detect low activity 
levels associated with both reduced (type I) as well as dysfunctional protein C 
(type II) (63-65). 
 
2.6.1 Activity assays 
       Numerous activity assays have been described that use different types of 
activators and detection methodologies (66). The majority of the proposed 
methods can be divided into three major steps: (1) isolation of PC from 
plasma, (2) PC activation, and (3) measurement of APC using either synthetic 







2.6.2 Immunological assays 
       Immunological assays for PC are usually based on the use of monoclonal 
antibodies against PC and include electroimmunoassays (EIA), 
radioimmunoassay (RIA),(67) and enzyme-linked immunosorbent assays 
(ELISA) (68,69) The advantages of these assays are their specificity, 
reproducibility and accuracy. However, since immunological assays measure 
all types of PC molecules in plasma without evaluating their function, they will 
not detect dysfunctional molecules (type II deficiency). 
 
2.7  Major components of the protein C pathway  
2.7.1 Protein C and APC 
       Protein C is converted to APC when thrombin complexes with TM (70). 
The activation of PC is facilitated by the EPCR, which appears to be primarily 
located on major blood vessels. In healthy individuals, circulating levels of PC 
and APC are 3,000–7,000 ng/ml and 1–3 ng/ml, respectively. Under normal 
conditions, circulating levels of APC are dependent on the concentrations of 
PC and thrombin. Infusing low concentrations of thrombin in healthy baboons 
results in concentrations of APC exceeding 200 ng/ml. Activation of the PC 
pathway in patients undergoing thrombolysis for acute myocardial infarction 
results, on average, in APC concentrations of 69 ng/ml, possibly related to the 
release of thrombin from lysing thrombus. Consequently, in the setting of a 
normal endothelium, activation of the PC pathway would be expected to result 
in an increase in circulating levels of APC. In severe sepsis, however, the host 
response leads to a generalized systemic dysfunction of the endothelium (71) 
. 
2.7.2  Thrombomodulin and EPCR 
 
       In severe sepsis, the host response also leads to a generalized systemic 
dysfunction of the endothelium (71). Thrombomodulin is required for activation 
of PC, and in vitro studies have shown that endotoxin and inflammatory 
cytokines can down regulate endothelial-surface TM. Thrombomodulin can 
also be cleaved by neutrophil elastases and released into the systemic 
circulation. In a study of pediatric patients with severe sepsis from 
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meningococcal infection, TM and EPCR were reduced in skin biopsy 
specimens, which can contribute to low levels of APC. EPCR, a type I 
transmembrane protein with homology to CD1d/major histocompatibility 
complex class I proteins involved in antigen presentation, facilitates the 
conversion of PC to APC. In vivo, a study reported that EPCR mRNA 
expression was up regulated in the liver, kidney, and lung 24 hours after cecal 
ligation and puncture in PC heterozygous mice (25). Gu and his colleagues 
demonstrated that intravenous injection of lipopolysaccharide increased 
EPCR mRNA levels in the lung and heart, and increased (by approximately 
four fold at 6 hours, the peak of expression) the soluble EPCR serum level in 
rodents. However, the cell surface EPCR levels in the lung and heart changed 
little in response to endotoxin challenge, suggesting that the increase of 
mRNA may compensate for the increased shedding of the receptor from the 
endothelium (72). In severe sepsis patients, deficiencies in the PC pathway 
can contribute significantly to the decrease in APC generation (72). In 
summary, low concentrations of circulating APC can be explained by low PC 
concentrations, down regulation or shedding of TM and EPCR, and/or APC 
trapping by soluble EPCR. The low levels of PC and APC provide a scientific 
rationale for giving exogenous APC to patients with sepsis-induced 
coagulopathy and inflammation. 
 
2.8 The activation complex 
 
       The key feature of the PC pathway resides in the ability of the pathway to 
respond to the presence of thrombin. As the thrombin concentration rises, 
much of the thrombin binds to TM, primarily on the endothelial cell surface 
(Figure 2.7), leading to the activation of PC. PC activation is enhanced 
approximately 20-fold in vivo when PC is bound to the EPCR (8). Relative to 
free thrombin, thrombin bound to TM is inactivated much more rapidly by 
antithrombin and the PC inhibitor, with an estimated half-life for inactivation of 
approximately 2 seconds (73).Thus, once thrombin generation ceases, the PC 
activation complex quickly stops generating APC. PC and APC bind to EPCR 
with equal affinity. By having EPCR participate in PC activation, it guarantees 
that EPCR will be “loaded” with APC. APC bound to EPCR can be inactivated 
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by plasma protease inhibitors (α1-antitrypsin and PCI) at approximately the 
same rate as free APC (half-times approximately 15 min) (74). This slow 
inactivation allows APC bound to EPCR to signal cells. Cleavage of PAR-1 by 
the APC-EPCR complex has been implicated as one such cell-signaling 
mechanism, the most important of which seems to be related to anti apoptotic 
activities (9). 
 
Figure 2.7. The role of the PC pathway in regulating coagulation. Endotoxin leads to 
initiation by a variety of mechanisms, primarily by eliciting tissue factor expression. 
This leads to formation of factor VIIIa-IXa complexes and factor Va-Xa, and ultimately 
to thrombin generation. Thrombin can either cause fibrin formation and platelet and 
endothelial cell activation, or it can bind to (TM), where it rapidly activates PC. This 
process is enhanced by the EPCR. Once APC dissociates from EPCR, it binds to 
protein S, and this complex then inactivates factors Va and VIIIa. In the case of factor 
VIIIa, the process is enhanced further by factor V. (75). 
 
 
2.9 Functions of APC 
       In addition to inactivating factors Va and VIIIa (Fig2.7), APC has been 
shown to have anti-inflammatory, anti apoptotic, and anticoagulant activity at 
the cellular level. The anti apoptotic activity appears to be mediated, at least 
in part, by the APC-EPCR complex cleaving PAR-1. Since EPCR is 
expressed primarily on endothelium, but PAR is located on many cells, the 
EPCR dependence probably allows for preferential activation of this receptor 
on endothelium,(9) thereby avoiding platelet and neutrophil activation that 
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might otherwise occur. The anti-apoptotic activity of APC mediated through 
PAR-1 activation is supported by the recent observation that either APC (in 
an EPCR-dependent fashion) or PAR-1 activation peptides could protect 
mice from ischemic stroke (10). APC activation of PAR-1 would not appear 
to account for other cellular responses associated with APC treatment in 
vivo or with cells. APC has been shown to inhibit TNF-α release in vivo, 
TNF-α release from monocytes, and nuclear factor-κB nuclear  
translocation. In addition, APC has been shown repeatedly to block 
leukocyte adhesion in vivo, something that PAR-1 activation should 
increase. Finally, APC has been reported to inhibit  TF  expression, while 
PAR-1 activation increases (76).  
 
2.10 Physiology of the protein C pathway 
 
       Thrombomodulin is located on the endothelium; in general, the number of 
copies per endothelial cell appear by immunohistochemistry to vary <10-fold 
among vascular beds (the brain microcirculation being an exception, where 
TM expression is very low) (77). From simple geometry, the endothelial cell to 
blood volume ratio increases hundreds of fold as blood moves from the large 
vessels to the capillaries. Assuming 100,000 copies of TM per endothelial cell, 
a reasonable estimate of the TM concentration in the capillaries is in the range 
of 100 to 500 nmol/L. Therefore, as thrombin passes through microvascular 
beds, the high concentrations of TM will tend to remove almost all of the 
thrombin, leading to rapid thrombin inactivation by inhibitors, direct blockage 
of thrombin procoagulant reactions, and rapid activation of PC (78). 
Consistent with this concept, severe defects in the PC pathway are associated 
with microvascular thrombosis, particularly of the skin (purpura fulminans). In 
the case of PC deficiency, progression and reversal (assuming no tissue 
death) of these lesions can be prevented and reversed rapidly by 
administration of PC (79). These lesions look similar to those that can appear 
in septic patients, particularly patients with meningococcemia, where PC 




2.11 Regulation of the protein C pathway 
Down-regulation 
       Both TM and EPCR can be down-regulated at the transcriptional level by 
inflammatory cytokines like IL-1β and TNF-α. In addition, TM activity can be 
dramatically reduced by oxidants released from leukocytes. Finally, leukocyte 
elastase rapidly releases soluble forms of TM that have considerably less 
activity than the cellular form because they no longer have the EPCR 
acceleration effect and they do not contain the chondroitin for high-affinity 
thrombin binding. The net effect of this inflammatory attack on the vessel wall 
is to decrease PC activation and TM expression. This has been shown in a 
subgroup of patients with meningococcemia, and direct assays of APC levels 
in patients with severe sepsis show a considerable range of PC activation 
dysfunction (81). Thrombin and IL-1β can lead to release of soluble EPCR, 
decreasing the PC activation potential. In the case of thrombin, however, this 
is offset by a thrombin dependent increase in EPCR gene transcription. 
Cellularly released proteins can also inhibit PC activation. Eosinophil major 
basic protein is a potent  inhibitor of  TM-dependent PC activation (82), 
potentially contributing to thrombosis in hyper eosinophilic heart disease. 
 
Up-regulation 
       Platelet factor 4 has been shown to increase PC activation rates 
approximately four fold in vitro (83). Release of platelet factor 4 from platelets 
at sites of vascular injury provides a potential mechanism for limiting thrombus 
growth downstream of the injury site. 
 
2.12 Genetic deficiencies of protein C 
       In many families, a PC gene abnormality co-segregates with PC 
deficiency and with a thrombotic phenotype (84). The human PC gene maps 
to chromosome 2q13-q14,(85) spans over 11 kb, and comprises a coding 
region (exons II to IX) and a 5' untranslated region encompassing exon I (86). 
Three polymorphic sites (–1654 C/T, –1641 A/G, and –1476 A/T) are located 
in the 5' nontranscribed region of the PC gene. In 44 unrelated individuals in 
whom familial studies could be performed, 3 of 8 possible haplotypes (CGT, 
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TAA, and CAA) were observed with frequencies of 0.33, 0.30, and 0.25, 
respectively (87). Interestingly, in a population of 240 patients and controls, 
subjects homozygous for the CGT combination had lower PC concentrations 
than subjects homozygous for the TAA combination (88). Each polymorphic 
site was analyzed in the 474 patients and controls of the Leiden 
Thrombophilia Study, and individuals with the homozygous CGT genotype 
were found to have a 50% to 100% greater risk of venous thrombosis than 
individuals with the homozygous TAA genotype (88).  
The physiologic importance of the PC system is most clearly demonstrated by 
the massive, usually lethal, thrombotic complications occurring in infants with 
severe homozygous protein C deficiency and the significantly increased risk 
for venous thrombosis in heterozygous deficient adults (89). The most 
commonly identifiable hereditary risk factor for venous thrombosis among 
whites involves an APC cleavage site mutation (Arg506Gln, factor V Leiden) 
that is the major target for factor Va inactivation by APC (90). Targeted 
deletion of the PC gene in mice results in perinatal lethality (91). 
Nevertheless, in the absence of fetal PC, embryogenesis and development 
occur, potentially due to maternal PC in the fetus. Although PC–null embryos 
develop at the expected Mendelian distribution until embryonic day 17.5, 
these embryos show extensive bleeding, coagulopathy, fibrin deposition, and 
liver necrosis. In moderately to severely deficient mice, PC levels of 1% to 
18% suffice for development and birth, although such mice are prone to early 
onset thrombosis and inflammation, indicating protein C’s physiological role as 
an antithrombotic and anti-inflammatory protein (92). 
2.13 Protein C as a biomarker    
       Abnormalities in coagulation parameters are commonly observed in 
patients with severe sepsis and have been associated with higher mortality. 
These include reductions of the major natural anticoagulants antithrombin III, 
tissue factor pathway inhibitor and PC. Studies have shown that more than 
80% of patients with severe sepsis had a baseline PC level below the lower 
limit of normal. Plasma PC levels decrease early in patients who develop 
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severe sepsis, often before clinical symptoms appear, and these levels remain 
low, gradually rising in patients who recover and survive (93). 
2.14 Therapeutic prospects 
       Reduced levels of PC are found in the majority of patients with sepsis and 
are associated with increased morbidity and mortality (94). Treatment with 
recombinant human APC reduces plasma levels of D-dimer and IL-6, and in 
the Recombinant Human Activated Protein C Worldwide Evaluation in Severe 
Sepsis (PROWESS) study resulted in a significant reduction in mortality in 
patients with severe sepsis. Despite the reported increased risk of bleeding 
with APC, and some controversy regarding its use over PC,  these results, 
based on insights into the relevant molecular mechanisms, highlight the 
potential of developing novel and effective approaches to treating sepsis, as 
well as other disorders associated with leukocyte-mediated tissue damage 
(95). Furthermore, the safety and efficacy of these approaches will most 
certainly be enhanced as assays are improved to measure circulating levels of 
APC and other relevant markers of inflammation, including soluble TM 
fragments and EPCR.  
Administration of recombinant forms of TM that encompass EGF1 through 
EGF6 are protective in a variety of animal models of tissue factor- or 
endotoxin-induced disseminated intravascular coagulation or lung injury (96).  
Although these forms of TM may be effective as anticoagulants, their clinical 
use for sepsis or inflammatory disorders is likely to be complicated by 
bleeding, similar to APC. Might the lectin-like domain of TM be efficacious as 
a therapeutic agent in sepsis, thereby sparing the bleeding side effect?. 
Studies suggest that this non anticoagulant form of soluble TM may modulate 
inflammation by attenuating mitogen activated protein kinase (MAPK) 
pathways and interfere with neutrophil–endothelial cell interactions. The 
clinical usefulness of this fragment of TM is being evaluated using in vivo 




2.15 systemic variables as a prognostic index in intensive 
care medicine 
 
       A group of variables have emerged that can possibly be used as gravity 
indices in all patients admitted to Al-Shifa ICU. One of these variables is the 
CRP, the acute phase parameter most used in the daily clinical practice that 
lately has received a renewed interest. CRP has several characteristics that 
make it a very interesting possibility as a gravity index in Intensive Medicine. It 
is produced in a non-specific manner as an answer to different types of 
pathologic events such as infection, inflammation or tissue necrosis. It is 
produced faster than most acute phase proteins and simultaneously has a 
shorter half-life (19 hours). There is no evidence of its catabolism or clearance 
rising in several groups of diseases and the values of CRP are not influenced 
by organic failure except severe hepatic failure ,it  is produced in the liver (98). 
Multiple organ dysfunction is a major cause of death in ICU patients (99). A 
number of inflammatory cells and mediators involved in the inflammatory 
response have been assessed for their role as potential markers of the 
presence and severity of the inflammatory response and organ failure (100). 
Serum levels of CRP, an acute-phase protein synthesized by the liver 
following stimulus by various cytokines including TNF-α and  IL-6, markedly 
increase within hours after infection or inflammation (101).  
2.16 Intensive care unit 
       An intensive care unit, is a specialized section of a hospital that provides 
comprehensive and continuous care for persons who are critically ill and who 
can benefit from treatment (102). Some patients are in an ICU for shorter 
periods of time than others, depending on the extent of their illness or injury. 
They may be admitted either as a planned admission after major surgery or as 
an emergency admission following an acute illness. 
Although the criteria for admission to an ICU are somewhat controversial—
excluding patients who are either too well or too sick to benefit from intensive 
care—there are four recommended priorities: 
 24
• Critically ill patients in a medically unstable state who require an 
intensive level of care (monitoring and treatment).  
• Patients requiring intensive monitoring who may also require 
emergency interventions.  
• Patients who are medically unstable or critically ill and who do not have 
much chance for recovery due to the severity of their illness or 
traumatic injury. 
• Patients who are generally not eligible for ICU admission because they 
are not expected to survive (103). 
Although the total number of US hospitals has declined in the past 2 decades, 
the number of ICU beds has risen ,  from 1985 to 2000 the cost of critical care 
medicine increased from $19.1 billion to $55.5 billion (104).  
The total number of Gaza Strip hospitals has increased in the past 8 years, 
the number of ICU beds has risen. More than 450 patients are admitted to AL-
Shifa ICU each year in the Gaza strip (AL-Shifa hospital). 
 An ICU is a consolidated area of a hospital where patients with acutely life 
threatening illnesses or injuries receive around the clock specialized medical 
and nursing care, such as mechanical ventilation and invasive cardiac 
monitoring (105). 
2.16.1 The common conditions requiring critical care 
       Patients with critical illness suffer from failure of one or more of their 
systems such as the heart, lung or kidneys. Heart attack, stroke, poisoning, 
pneumonia, surgical complications, major trauma as a result of road traffic 
accidents, a fall, burns, an industrial accident or violence are all examples of 
critical illnesses. Patients recovering from a major operation are also admitted 
to ICU (102). 
Infections are a common cause of ICU admission and can develop for many 
reasons while a patient is in the ICU. An infection, as well as age and pre-
existing medical conditions affecting the patient, may put them at risk of 
uncontrolled inflammation, which is called sepsis (103). 
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Overwhelming infection that causes at least one acute organ dysfunction is 
called severe sepsis. This occurs when the inflammatory response begins to 
affect the basic functions of the body (renal kidney failure and acute 
respiratory failure), and the patient becomes very sick. 
Acute renal failure (ARF) is a common complication in patients admitted to the 
ICU (106). Sepsis is also a well-known risk factor for the development of ARF, 
and 35 to 50% of ARF cases in the ICU can be attributed to sepsis. Mortality 
in this subgroup of patients is considerably higher than in other subgroups of 
ARF (107).  
 
2.16.2 Definitions of organ failure 
       Definitions of organ failure are shown in table 2.1 (108). 
 
Table (2.1) .  Table of organ dysfunction 




≤ 90; not fluid 
responsive 








80–51 50–21 ≤20 
Renal/creatinine, 
mg/dL 
2.0–3.4 3.5–4.9 ≥ 5.0 
Hepatic/bilirubin, 
mg/dL 
2.0–5.9 6.0–11.9 ≥ 12 
Fio2 = fraction of inspired oxygen, BP=Blood pressure,Pao2= partial pressure of oxygen. 
2.17 Related studies 
       Several studies have reported decreased PC concentrations in patients 
with sepsis syndromes. Moreover, a strong correlation between lower PC 
levels and worse outcome has been reported (109). Continuation or 
worsening of coagulopathy during the first days of severe sepsis has also 
been found to be associated with subsequent development of new organ 
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dysfunction and worse outcome (110). Activation of inflammatory pathways 
can, however, occur in a variety of clinical conditions in the ICU, including 
after surgical interventions and traumatic injury (111). Boldt and his 
colleagues reported considerable alterations in the hemostatic network in 
patients with severe trauma and those admitted to the ICU after neurosurgical 
procedures (111). PC concentrations were more markedly decreased in 
patients with sepsis compared to those with severe trauma and neurosurgery. 
Characterizing the evolution of PC concentrations and their possible 
relationship to morbidity and mortality may help in identifying high-risk groups 
and potential therapeutic targets.  
 
Other studies have shown that more than 80% of patients with severe sepsis 
had a baseline PC level below the lower limit of normal (99). Plasma PC 
levels decrease early in patients who develop severe sepsis, often before 
clinical symptoms appear, and these levels remain low, gradually rising in 
patients who recover and survive (112). 
 
Numerous reports have examined the predictive value of plasma PC levels in 
sepsis. These reports confirm the association between depressed PC levels 
and the increased likelihood of negative outcomes in sepsis, including time on 
a ventilator, time in the ICU, development of shock and increased mortality 
(113,114). PC levels less than approximately half the lower limit of normal are 
associated with a much greater risk for death (115). In a recent multivariable 
analysis with ICU mortality as the dependent variable (113), a minimum PC 
concentration of less than 45% was identified as an independent risk factor in 
surgical ICU patients. 
In studies of using recombinant human APC (Drotrecogin alfa) in adult 
patients with severe sepsis, endogenous PC and APC concentrations were 
measured in placebo-treated patients at variable time points during the first 4 
days of study participation. In a Phase II study, 80% of placebo-treated 
patients had no detectable levels of APC (lower limit of detection = 5 ng/ml). 
The remaining patients had transiently detectable levels that displayed no 
discernible pattern, and no patient had a level exceeding 20 ng/ml. In a Phase 
 27
III study, only 11 of 333 placebo-treated patients had measurable levels of 
APC (lower limit of detection = 10 ng/ml). In these 11 patients, only 13 of the 
36 total samples collected had measurable concentrations of APC, and only 
two samples contained concentrations exceeding 20 ng/ml. Data from studies 
with a small number of severe sepsis patients confirm that levels of 
endogenous APC are much lower than the therapeutic levels (45 ng/ml) 
achieved with Drotrecogin alfa  treatment, and are not sustained (116). 
Data from previous studies of drotrecogin alfa ,also show a strong association 
between very low PC levels and mortality in patients with severe sepsis. In the 
placebo arm of Recombinant Human APC (PROWESS) (35) no difference in 
mortality was identified between patients with normal PC levels  at baseline 
and those with moderate PC deficiency. In the former group, mortality was 
5.7% at day 4 and 26.7% at day 28, and in the latter group the corresponding 
percentages were 5.5% and 24.9%, respectively. However, patients who 
presented with severe PC deficiency had a markedly higher mortality both at 
day 4 (20%) and at day 28 (41.8%). 
In another study, the researchers analyzed the relationship between PC and 
indicators of organ failure in 312 patients admitted to the surgical ICU with an 
estimated length of stay of more than 48 hours. Changes in plasma PC levels 
were measured daily until patient discharge or death, and analyzed for their 
ability to predict mortality risk. The result was about half the patients had PC 
levels below the lower limit of normal of 50.6%. PC decreased further over the 
next three to four days before returning to normal by about two weeks, 
regardless of patient sex, source and type of admission, type of surgery, or 
the presence of sepsis (113). 
In a study assessed the association between early serum CRP concentrations 
and the development of organ failure and mortality in ICU patients.                                                  
It was found that in a heterogeneous ICU population, elevated concentrations 
of serum CRP in ICU admission are correlated with an increased risk of organ 
failure and death. Moreover, persistently high CRP concentrations are 
associated with a poor outcome (28).                                                                                                     
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CHAPTER III                                 Materials and Methods  
 
3.1 Materials  
3.1.1 Reagent kits  
 Four DiaChrom Protein C Kits (Chromogenic assay for measuring protein C   
in plasma ) 
Two PT, APTT kits. 
Four CRP kits ( C- reactive protein a latex slide test). 
  
3.1.2  Instruments and disposables  
Spectrophotometer for chromogenic assays, with a wave-length at 405nm. 
Stago for PT, APTT. 
Stop watch. 
Calibrated pipettes 10µl -1000µl . 
Centrifuge . 
Deep freezer (-70°C) for specimen storage. 
Incubator 37°C 
EDTA tubes. 
Chemistry tubes . 
Sodium citrate anticoagulant 0.109 M in a silicon glass tubes. 
Distilled water, preferably sterile 
Physiological saline (0.85%NaCl) 
DiaMed Reference Plasma (REF 330061) 
Plastic tubes 
Yellow and blue tips 
Alcohol swab 
Syringes and needles 
Plasters  
 
3.2 Study population 
This study is a cross sectional study. However, due to different problems we 
recruited only 85 patients and 85 healthy controls. So the total number of 
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subjects included in this study was 170 and they were divided into the 
following two groups:  
 
A-  Patients 
All patients admitted to the ICU at AL-Shifa hospital, between March and July 
2008, were screened within 24 hr from admission. Exclusion criteria were age 
younger than 15 yr and patients suffering from malignancy. Patients were 
followed up until ICU discharge.  
 
B-  Healthy controls  
Healthy subjects, aged 15 to 70 years, were recruited between July and 
august 2008 from a health care center to which they had been referred for a 
routine check up at  Al-Remal clinic. None of these subjects had a history of 
arterial disease (stroke, myocardial infarction, angina, or peripheral vascular 
disease), venous thrombosis (pulmonary embolism or DVT), or known 
malignancy. 
 
3.2.1 Permissions and ethical consideration  
According to research ethics, permission was obtained from the Helsinki 
Committee (Annexes) for sample collection and consents were also obtained 
from each patient for the purpose of the study and drawing extra blood . 
 
3.3 Methods  
3.3.1 Sample collection and analyses 
Blood samples were collected at baseline; routine parameters of liver and 
kidney dysfunction/failure and complete blood count (CBC) were measured at 
Al-Shifa hospital laboratories, prothrombin time (PT), partial thromboplastin 
time (PTT) and international normalized ratio (INR) test at Balsam Laboratory 
using automated measures. Plasma PC concentrations were determined 
chromogenically on citrated blood, plasma was obtained by centrifugation at 
3000 rpm for 20 minutes at 18°C or below, and plasma transferred into a 
plastic tube and stored at –70°C until batch analysis, CRP testing was 
performed in the central laboratory at Al-Remal clinic. 
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3.3.1.1 Laboratory Investigations 
Venous blood was collected onto 0.109 M  sodium  citrate (1:10)  and  plasma  
was  kept frozen   until   use  for   PC  activity.  PC  antigen  (PC ag.)   was   
assayed   by  an chromogenic  assay .  Control  plasma  was  assayed  within  
2  months  using  a pool of plasma  from  85 healthy  men  and  women  aged 
15 to 70, to  construct  the  reference curve.  
Parameters of Liver and kidney  dysfunction/failure were determined using a 
Hitachi 911 clinical chemistry analyzer (Roche Diagnostics, Indianapolis, IN). 
complete blood count (CBC), was assayed by an cell dyne hematology 
analyzer. 
PT, APTT and INR, were assayed by Diagnostica Stago. 
3.3.1.2 Data Collection 
Data recorded on admission included age, sex,  primary diagnosis. The 
laboratory indices of liver, kidney and coagulation dysfunction/failure 
(including platelets count, PT, APTT, INR, serum creatinine, urea, ALT, AST, 
glucose, TP, ALB, Na+, K+ , Ca+2, CRP titer and PC activity) were recorded. 
 
3.3.2 Sample Processing  
3.3.2.1 Protein C assay  
DiaChrom PC kit is a chromogenic assay for measuring PC activity in human  
citrated plasma. 
A. Principle of the assay  
In the DiaChrom PC assay PC is measured following specific activation with 
Protac -an enzyme extracted from snake venom- (Agkistrodom C Contortrix), 
APC then specifically cleaves the specific substrate DiaZym APC, releasing 
paranitroanilline (pNA) which is measured at 405nm.There is a direct 
relationship between colour development and PC activity in the tested plasma. 
                                                 protac 
                 Protein C                                           APC 
                                                  APC 
                 DiaZym  APC                                Peptide + pNA      
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B. Kit components  
      R1: 
Reagent 1: Protac, about 0.080 U. Highly purified specific PC activator 
extracted from the Agkistrodom C . Contortix snake venom ,lyophilized and 
stabilized, 3 vials containing about  0.080 U of Protac (to be reconstituted with 
2.5ml of distilled water). 
 
     R2: 
Reagent 2: DiaZym APC 
Chromogenic substrate, specific for APC (DiaZym APC), lyophilized: 3 vials 
containing  4mg of DiaZym APC (to be reconstituted with 2.5ml of distilled 
water). 
Further reagents required 
▪ Distilled water, preferably sterile 
▪ Physiological saline (0.9%NaCl) 
▪ DiaMed Reference Plasma (REF 330061) 
 
C. Test Procedure:  
Diachrom PC kit is designed for use in kinetic methods. 
The assay is performed at the controlled temperature of 37°C and the colour 
development is measured at 405 nm. 
 
D. Assay protocol   
Manual method  
The test samples was diluted, the controls and the calibration solutions 1:2 
with physiological saline (0.15M Sodium Chloride). 
Reagents  
Calibrators, Controls or tested plasmas, diluted 1:2                     30 µl                           
R1 :Proac® preincubated at 37 ºC                                 125µl 
Mixed and Incubated for 5 min at 37ºC   
R2:Diazym APC Substrate preincubated  at 37ºC    125µl 
After mixing the change of optical density at 405 nm for one 
minute was measured. 
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E. Calculation of results  
The standard curve (Figure 3.1) was established by plotting the mean OD-
values of the standards 1-4 on the ordinate, X-axis versus their respective 
Protein C concentrations on the abscissa, Y-axis. 
Concentrations of the unknown samples were directly read off in % against 
the respective OD values. 
Example of calibration curve 
▪ The calibration curve was established by diluting DiaMed Reference   
plasma (REF 330061) 1:1,1:2, 1:4 and  a blank with saline.  
▪ The Calibrators 1-4 were diluted with saline 1:2 (e.g.100µl calibrator 1 ,100µl 
saline. 
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Expected values  
By definition, the 100% protein C activity corresponds to the concentration in a 
normal human citrated plasma pool, obtained by pooling plasmas from healthy 
males or females aged from 18 to 55 years, and not on any medication. The 
protein C activity in adults is usually between 70 and 140%. 
Protein C concentration < 60% indicates the presence of a deficiency, which 
should be confirmed by another test and / or by testing another plasma 
sample from the patient. The protein C activity is decreased in neonates. 
 
3.3.2.2 CRP assay  
CRP level were determined using CRP latex kit (Teco Diagnstics). 
A. Principle of the assay 
The CRP reagent kit is based on an immunological reaction between CRP 
antisera bound to biologically inert latex particles and CRP in the test 
specimen. When serum containing greater than 0.8 mg/dl CRP is mixed with 
the latex reagent, visible agglutination occurs. 
B. Reagents and materials provided 
 1- CRP latex Reagent: A suspension of uniform polystyrene particles coated 
with monospecific antihuman CRP in glycine buffer, pH 8.8 ± 0.5, reagent 
sensitivity adjusted to approximately 0.8 mg/dl. MIXED WELL BEFOR 
USING. 
2- CRP positive control serum: A stabilized prediluted human serum 
containing more than 0.8 mg/dl CRP. 
3- CRP negative control serum: A stabilized prediluted human serum non-   
reactive with the test reagent. 
4- Glycine-saline buffer (20x): pH 8.2± 0.1: A diluent containing 0.1M glycine- 
and 0.15M NaCL. Buffer was diluted  according to instructions on the label 
before using. 






C. Procedure (semi-quantitative Test ) 
 1- Six test tubes: 1:2, 1:4, 1:8, 1:16, 1:32, 1:50. 
 2- Sample was diluted according to dilution factor on each test tube with 
diluted saline solution. Saline solution was diluted with distilled water before 
use. 
3- One drop of each of positive and negative controls were placed onto 
separate slide fields. One drop of each dilution on successive fields of the 
reaction slides was delivered.  
4- The CRP latex reagent was gently resuspend and added one drop to each 
test field. 
5- Slide was mixed well with the flat end of the pipette. The slide was gently 
rocked for three (3) minutes and read immediately under direct light. 
6- The titer of the serum is the reciprocal of the highest dilution exhibiting a 
positive reaction multiplied by the concentration of the positive control. 
   mg/dl of serum = concentration of positive control × reciprocal of last dilution 
showing  a positive result 
D. Quality Control 
1- CRP positive and negative control were included in each test batch. 
2- Acceptable performance was indicated when a uniform milky suspension 
with no agglutination was observed with the CRP negative control and 
agglutination with large aggregates was observed with the CRP positive 
control.  
E. Interpretation  
Negative result: A negative reaction is indicated by a uniform milky 
suspension with no agglutination as observed with the CRP negative control. 
Positive result: A positive reaction is indicated by any  observable  
agglutination in the reaction mixture. The specimen reaction was compared to 
the CRP of the negative control . (figure 3.2)  
 




F. Expected Values  
CRP in healthy individuals is approximately 0.02-1.35mg/dl. The mean value 
in adults is 0.047mg/dl. 
 
3.4 Statistical methods 
Data were analyzed using SPSS version 13.0 for windows. Data are 
presented as mean ± SD, frequencies and percentage unless other wise 
indicated. 
►For all analyzed P value less than 0.05 was considered significant. 
►The correlations between numerical data were analyzed by Pearson's 
correlation coefficient and Chi-square test of independences was used for 
correlation between nominal or order data. 
►Independent  sample t test was used for comparison between the patients 
and controls groups and used to comparison between the two group of protein 
C (less than or equal 70% and more than 70%) 
►One way ANOVA was applied. 
►LSD multiple comparisons for means of the CRP groups that had 
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4.1. Characteristics of the patient group       
The sample size of the study was 170 subjects. The case-control ratio is 1:1 
matched by age and gender. Of 150 patients admitted to ICU during the study 
period, 85 patients (57 male and 28 female) met the inclusion criteria and 
were enrolled in the study. The characteristics of the study group are 
presented in table 4.1 and fig.4.1. Forty patients (47.1%) are Less than 30 
years, 14 patients (16.5%) are 30 to 40 years, and 31 patients (36.5%) are 
more than 40 years. Twenty four patients (28.2%) were admitted after 
Explosive injury (E.I), 16 patients (18.8%) were admitted after operative 
procedures, 5 patients (5.9%) were admitted as acute renal failure (ARF), 4 
patients (4.7%) were admitted as RTA, 5 patients (5.9%) as diabetic 
ketoacetosis (DKA), 3 patients (3.5%) as chronic obstructive pulmonary 
disease (COPD), 6 patients (7.1%) as head trauma and head falling, and 22 
patients (25.9%) were others  primary diagnosis. The length of stay was 1-4 
days in 65 patients (76.5%), 5-8 days in 13 patients (15.3%), and 9 days and 
more was 7 patients (8.2%). The overall ICU outcome rate was 20% (n = 17 ) 




     Figure 4.1. Characteristics of the patient group on admission to the ICU. 
     EI = Explosive injury, ARF= acute renal failure, RTA= Road traffic accident, DKA = diabetic 
     ketoacetosis, COPD = chronic obstructive pulmonary disease. 
Primary Diagnosis
others


























Table 4.1 Characteristics of the patient group upon admission to the ICU (n = 
85)   
  
Variable  Categories  Frequency  Percent  
< than 30 40  47.1  
30 to 40 14  16.5  Age (years)  
> than 40 31  36.5  
 Total 85  100  
Male 57  67.1      
 Gender  Female 28  32.9  
 Total 85  100  
E.I  24  28.2  
post operative 16  18.8  
ARF 5  5.9  
RTA 4  4.7  
DKA 5  5.9  
COPD 3  3.5  





Primary diagnosis  
 
Others* 22  25.9  
 Total  85  100  
survivors 57  67.1  
non survivors 17  20  
 
ICU outcome 
 critically ill 11  12.9  
 Total 85  100  
1-4 days 65  76.5  
5-8 days 13  15.3  
 
length of stay 
9 days or more  7  8.2  
 Total 85  100  
 
EI = Explosive injury, ARF= acute renal failure, RTA= Road traffic accident, DKA = diabetic 
ketoacetosis, COPD = chronic obstructive pulmonary disease.  
*Others=gastrointestinal, urogenital, epilepsy, hyperthyroidism, pre-eclampsia, liver cirrhosis, 


















4.2. Relationship between primary diagnosis and ICU outcome. 
 
Table 4.2 revealed no significant relation  (df=14, p=0.08) between the 
primary diagnosis and ICU outcome, Pearson Chi-Square=  21.9212. As 
shown that 57 out of 85  patients were survivors , 17 of 24 patients (29.8%) 
had E.I, 11 of 16 patients (19.3%) had operations, 2 of 5 patients (3.5%) had 
A.R.F., 3 of 4 patients (5.3%) had RTA, 5 patients (8.8%) had DKA, 1of 3 
patients (1.8%) had COPD, 5 of 6 patients (8.8%) had head trauma and head 
falling and 13 of 22 patients (22.8%) had others diagnosis. 
 
And that 17 of 85 patients were non survivors, 1 of 24 patients (5.9%) had EI, 
3 of 16 patients (17.6%) had operative, 3 of 5 patients (17.6%) had ARF, 2 of 
3 patients (11.8%) had COPD, 1 of 6 patients (5.9%) had head trauma and 
head falling, 7 of 22 patients (41.2%) had others diagnosis. 
 
And that 11 of 85 patients were critically ill , 6 of 24 patients (54.5%) had EI, 2 
of 16 patients (18.2%) had operations, 1 of 4 patients (9.1%) had RTA,2 of 22 
patients (18.2%) had others diagnosis.  
 
Table 4.2 Relationship between primary diagnosis and ICU outcome. 
ICU outcome 





Count 17 1 6 24 
EI % within survivors ,non survivors 29.8% 5.9% 54.5% 28.2% 
Count 11 3 2 16 
post operative % within survivors ,non survivors 19.3% 17.6% 18.2% 18.8% 
Count 2 3  5 ARF % within survivors ,non survivors 3.5% 17.6%  5.9% 
Count 3  1 4 RTA % within survivors ,non survivors 5.3%  9.1% 4.7% 
Count 5   5 DKA 
 % within survivors ,non survivors 8.8%   5.9% 
Count 1 2  3 
COPD 
% within survivors ,non survivors 1.8% 11.8%  3.5% 
Count 5 1  6 head trauma and head falling 
 % within survivors ,non survivors 8.8% 5.9%  7.1% 




% within survivors ,non survivors 22.8% 41.2% 18.2% 25.9% 
Count 57 17 11 85 Total % within survivors ,non survivors 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=  21.9212 df = 14 P-Value= 0.080 
 
EI = Explosive injury, ARF= acute renal failure, RTA= Road traffic accident, DKA = diabetic 
ketoacetosis, COPD = chronic obestructive pulmonary disease.  
*Others=gastrointestinal, urogenital, epilepsy, hyperthyroidism, pre-eclampsia, liver cirrhosis, drug 





4.3. Control group 
The characteristics of control group are summarized in table 4.3  
 
Table 4.3 Characteristics of controls group (n =85 )  
Variable  Categories   Frequency  Percent  
Male 57  67.1  Gender Female 28  32.9  
 Total 85  100.0  
< than 30  40  47.1  
               30 to 40  14  16.5  
> than 40  31  36.5  Age (years)  
Total 85 100.0  
  
AS shown in table 4.4. there was high statistically significant difference 
between the mean of variables levels of patients and the mean of variables 
levels of controls. 
  










Blood glucose (mg/dL) 178.5 147.3 93.7 18.4 0.000 
Urea (mg/dL)  54.2 41.5 23.9 6.9 0.000 
Creatinine (mg/dL) 1.3 1.4 0.7 0.2 0.000 
ALT(U/L)  45.9 36.8 22.7 12.7 0.000 
AST(U/L) 113.0 431.1 18.5 5.6 0.047 
TP (g/dL) 5.4 1.2 7.2 0.2 0.000 
Alb (g/dL) 3.0 0.8 3.3 0.2 0.001 
TB (mg/dL) 0.9 0.6 0.7 0.1 0.000 
DB(mg/dL) 0.4 0.3 0.3 0.04 0.018 
Ca+2 (mg/dL) 8.7 0.9 10.4 0.4 0.000 
WBC (109/L) 11.8 6.6 7.1 1.6 0.000 
RBC (1012/L) 3.9 0.9 4.8 0.5 0.000 
Hb (gm/dl) 11.0 2.2 13.8 1.4 0.000 
PLT (109/L) 184.2 110.2 265.5 59.8 0.000 
PC (%) 63.1 23.7 95.1 7.9 0.000 
CRP (mg/dL) 1.6 0.8 2 0 0.000 
Neutrophil (%) 83.1 11.6 58.4 8.4 0.000 
P<0.05:significant 
ALT=Alanine aminoransferase, AST=Aspartate aminotransferase, TP=Total Protein, Alb= 
Albumin, TB=Total Bilirubin, DB=Direct Bilirubin, Ca+2=calcium, WBC= White blood cells, 









4.4  Intensive care unit  length of stay, and protein C concentrations 
Table 4.5 shows that the mean of ICU length of stay (3.8± 4.0) in patients with 
PC concentration ≤70% is higher than that in patients (3.1± 4.2) with PC 
concentration >70%. The mean of length of stay in ARF patients (1.6±0.9) 
was the lowest compared with other patients. The length of stay among 
patients who had CRP <10mg/dl (5.6±6.2) was the highest compared with 
other two groups. Protein C concentrations % decreased in both survivors 
(68.7±23.6%), non survivors (50.5±14.3%), and critically ill (53.5±26.7%), but 
were lower in non survivors compared to survivors. 
Table 4.5. Intensive care unit  length of stay, and protein C concentrations 
according to primary diagnosis, gender, age, ICU outcome and CRP levels.  
Length of stay Protein C % 







EI 24  4.4  5. 3  63.5  26.2  
Post operative 16  2.7  2.4  61.7  20.5  
ARF 5  1.6  0.9  55.2  19.9  
RTA 4  8.8  7.7  53.0  22.5  
DKA 5  1.8  0.8  62.6  18.8  
COPD 3  7.0  8.7  53.7  2.3  
Head trauma and 
head falling 











Others* 22  2.6  1.8  67.9  26.5  
 Total  85  3.6  4.1 63.1  23.7 
Male 57  4.0  4.4  61.8  24.2  Gender Female 28  2.6  3.3  65.6  22.9  
 Total 85  3.6  4.1 63.1  23.7 
< than 30  40  4.5  5.0  63.9  24.4  
30 to 40  14  2.4  1.8  68.5  22.8  Age (years) 
>than 40  31  2.9  3.2  59.6  23.3  
 Total 85  3.6  4.1 63.1  23.7 
survivors 57  3.8  4.4  68.7  23.6  
non survivors 17  3.3  4.0  50.5  14.3  
ICU outcome 
 critically ill 11  2.8  2.4  53.5  26.7  
 Total 85  3.6  4.1 63.1  23.8 
≤70% 56  3.8  4.0  49.4  13.8   
PC  categories >70%  29  3.1  4.2  89.5  14.5  
 Total  85  3.6  4.1 63.1  23.7 
< 10  25  5.6  6.2  61.8  27.4  
        10-40  13  2.2  1.3  72.2  25.5  C-Reactive protein(mg/dl)  >40  47  2.8  2.6  61.3  20.9  
 Total 85  3.6  4.1 63.1  23.7 
 
E.I = Explosive injury, A.R.F= acute renal failure, R.T.A= Road traffic accident, D.K.A = 
diabetic ketoacetosis, C.O.P.D = chronic obestructive pulmonary disease, PC=protein C.  
*Others=gastrointestinal, urogenital, epilepsy, hyperthyroidism, pre-eclampsia, liver cirrhosis, 




4.5 Relationship between protein C with gender among patient and 
control group 
Table 4.6 revealed that there was no significant difference between PC means 
in male patients (61.8 ± 24.2) and female patients (65.6± 22.9). Also, there 
was no significant difference between male (94.7± 7.6) and female control 
group (95.9± 8.5)  regarding PC average. 
Table 4.6. Relationship between protein C with gender among patient and 
control group  
Protein C concentration 
Control group (n=85)  Patients (n=85) 







7.6 94.7 24.2  61.8  57 Male  
8.5 95.9  22.9  65.6 28 Female  




































4.6. Evaluation of protein C concentration upon admission into ICU.  
 
The initial PC concentration was below the lower limit of normal in 65.9% of 
patients (n = 56). The evaluation of PC levels upon admission to the ICU, 
stratified by the primary diagnosis  is presented in fig. 4.2. Protein C 
concentration decreased significantly in all patients irrespective of sex and 
diagnosis. Initial PC concentrations were lower in patients with RTA (n=4), 
compared with those who had COPD (n=3), ARF (n=5), post operative (n=16), 
DKA (n=5), EI (n=24), head trauma and head falling (n=6) and others (n=22) 
(Table 4.1,4.5). The minimal value reached was more pronounced in patient 
with RTA and EI compared with the other diagnosis  and control group (fig. 

























Figure 4.2 Box plots representing the protein C concentration (%) according to the 
primary diagnosis upon admission to ICU and controls. The dashed line represents 





4.7 Relation between the protein C concentrations, organ    
dysfunction/failure, and ICU outcome. 
 
The minimum PC concentration correlated negatively with the parameters of 
organ dysfunction. all patients with abnormal parameters of organ dysfunction 
had a  minimum PC concentration below the lower limit of normal. 
 
 
4.7.1 Average of renal function tests among patients by protein C.  
 
Table 4.7 revealed no significant difference (t=1.552,p=0.124) between PC ≤ 
70% patients (59.2±46.1mg/dl) and PC >70% patients (44.6±29.0 mg/dl) 
regarding urea average. There was no significant difference (t=0.815 
,p=0.417) between PC ≤ 70% patients (1.4±1.2 mg/dl) and PC >70% patients 
(1.2 ±1.2 mg/dl) regarding  creatinine  average. And  no significant  difference 
(t= -1.542,  p=0.129), (t= -1.165, p=0.249), (t=0.365,p=0.718), (t=-0.525, 
p=0.601)  and (t= -0. 459, p=0.649), respectively, between PC ≤ 70% patients 
(5.2 ±1.2 g/dl), (2.9±0.8 g/dl), (143.1±8.6 mmol/L), (4.3±1.0 mmol/L), (8.7±0.9 
mg/dL), respectively and PC >70% patients (5.7±1.3g/dl), (3.1±0.8 g/dl), 
(142.3±7.8 mmol/L),(4.4±1.1 mmol/L),(8.8±1.3 mg/dL), respectively regarding 
TP, ALb, Na+,  K+ and Ca+2  averages. 
 
Table 4.7 Average of renal function tests among patients by protein C. 
Protein C ≤70 % Protein C >70% 
Variable 




Urea (mg/dL) 59.2 46.1 44.6 29.0 0.124 
creatinine(mg/dL) 1.4 1.2 1.2 1.8 0.417 
TP (g/dl) 5.2 1.2 5.7 1.3 0.129 
ALb (g/dl) 2.9 0.8 3.1 0.8 0.249 
Na+(mmol/L) 143.1 8.6 142.3 7.8 0.718 
K+ (mmol/L) 4.3 1.0 4.4 1.1 0.601 
Ca+2  (mg/dL) 8.7 0.9 8.8 1.3 0.649 
 










4.7.2 Average of  hepatic function tests among patients in relation to 
protein C. 
As shown in table 4.8 among patients there was no significant difference 
(t=0.767,p=0.445) between PC ≤ 70% patients (110.6±449.6 U/L) and PC 
>70% patients (46.3±31.1 U/L) regarding ALT average. There was no 
significant difference (t=0.613,p=0.542) between PC ≤ 70% patients (133.7± 
527.6 U/L) and PC >70% patients (73.1±91.2 U/L) regarding AST average. 
There was no significant difference (t= -1.858,p=0.067) between PC ≤ 70% 
patients (0.8±0.04 mg/dL) and PC >70% patients (1.0±1.0 mg/dL) regarding 
TB average. Also there was no significant difference (t= -1.852,p=0.068) 
between PC ≤ 70% patients (0.4±0.03mg/dL) and PC >70% patients (0.5±0.5 
mg/dL) regarding DB average. 
Table 4.8 Average of  hepatic function tests among patients in relation to 
protein C.  
Protein C ≤ 70 % Protein C >70% 
Variable 





ALT  (u/L) 110.6 449.6 46.3 31.1 0.445 
AST (u/L)  133.7 527.6 73.1 91.2 0.542 
TB (mg/dL) 0.8 0.04 1.0 1.0 0.067 
DB (mg/dL) 0.4 0.03 0.5 0.5 0.068 




4.7.3 Average of  coagulation tests among patients by protein C.  
Table 4.9. revealed the presence of significant difference (t= -2.221, p=0.030) 
between PC ≤ 70% patients (3.8±0.8*1012/L) and PC >70% patients 
(4.3±0.9*1012/L) regarding RBC average.  There was significant difference (t= 
-2.548 ,p=0.013) between PC ≤ 70% patients (10.6±2.1 gm/dl) and PC >70% 
patients (11.8±2.2 gm/dl) regarding Hb average. There was significant 
difference(t=-2.063,p=0.042) between PC ≤ 70% patients (166.8±111.6*109/L) 
and PC >70% patients (217.8±100.9*109/L) regarding PLT average. There 
was significant difference (t= 2.089 ,p=0.043) between PC ≤ 70% patients 
(48.7±29.9 sec.) and PC >70% patients (30.1±11.1 sec.) regarding PTT 
average. In contrast, there was no significant difference (t= 0.643, p=0.522) 
between PC ≤ 70% patients (12.2±7.3*109/L) and PC >70% patients 
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(11.2±5.1*109/L) regarding WBC average. There was  no significant difference 
(t= 1.312 ,p=0.194) between PC ≤ 70% patients (84.6±11.3 %) and PC >70% 
patients (80.7±12.0 %) regarding Neutrophil average.  And no significant 
difference (t= 1.784,p=0.082) between PC ≤ 70% patients (32.0±28.8 sec.) 
and PC >70% patients (17.0±3.3 sec.) regarding PT average. There was no 
significant difference (t= 1.788,p=0.081) between PC ≤ 70% patients (3.0±2.8) 
and PC >70% patients (1.6±0.5) regarding INR average. 
 
Table 4.9. Average of  coagulation tests among patients by protein C.  
Protein C ≤ 70 % Protein C >70% 
Variable 




 WBC (109/L) 12.2 7.3 11.2 5.1 0.522 
RBC (1012/L) 3.8 0.8 4.3 0.9 0.030 
Hb (gm/dl) 10.6 2.1 11.8 2.2 0.013 
Neutrophil % 84.6 11.3 80.7 12.0 0.194 
PLT (109/L) 166.8 111.6 217.8 100.9 0.042 
PT (sec.) 32.0 28.8 17.0 3.3 0.082 
PTT( sec.) 48.7 29.9 30.1 11.1 0.043 
INR 3.0 2.8 1.6 0.5 0.081 
WBC= White blood cells, RBC= Red blood cells, Hb= Hemoglobin, PLT= platelets count, PT= 





4.7.4 Average of  pulmonary tests among patients in relation to protein 
C. 
 
As shown in table 4.10 there was no significant difference (t= -0.514, p=0.612) 
between PC ≤ 70% patients (7.3±0.2) and PC >70% patients (7.4±0.1) 
regarding PH average. There was no significant difference (t= 0.091 , 
p=0.928) between PC ≤ 70% patients (41.9±9.4 mmHg) and PC >70% 
patients (41.6±9.8 mmHg) regarding PCO2 average. There was no significant 
difference (t= -1.708,p=0.107) between PC ≤ 70% patients (18.3±5.6mEq/L) 
and PC >70% patients (24.7±10.3 mEq/L) regarding HCO3 average. There 
was no significant difference (t= 0.613, p=0.545) between PC ≤ 70% patients 
(87.0±13.7%) and PC >70% patients (83.4±17.0%) regarding So2 average. 
There was no significant difference (t= 0.441, p=0.673) between PC ≤ 70% 
patients (0.5±0.1) and PC >70% patients (0.4) regarding fio2 average. There 
was  no significant difference (t= -1.516 , p=0.143) between PC ≤ 70% 
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patients (-5.4±9.9) and PC >70% patients (1.8±13.6) regarding BE average. 
And no significant difference (t= 0.857, p=0.401) between PC ≤ 70% patients 




Table 4.10. Average of  pulmonary tests among patients in relation to protein C. 
Protein C ≤ 70 % Protein C >70% 
Variable 




PH 7.3 0.2 7.4 0.1 0.612 
PCO2( mmHg) 41.9 9.4 41.6 9.8 0.928 
HCO3 (mEq/L)  18.3 5.6 24.7 10.3 0.107 
SO2 %  87.0 13.7 83.4 17.0 0.545 
FiO2  0.5 0.1 0.4 . 0.673 
BE -5.4 9.9 1.8 13.6 0.143 
PO2( mmHg) 61.7 32.3 50.1 22.2 0.401 
PCO2= partial pressure of carbon dioxide, HCO3= bicarbonate, SO2= oxygen saturation, 



























4.8. Relation between protein C levels and ICU outcome 
 
Table 4.11 shows that the fifty-six of 85 patients (65.9%) had base line PC 
levels below the lower limit of normal. Thirty patients of 57 (35.3%) had base 
line PC levels below the lower limit of normal were survivors, and 16 of 17 
patients (18.8%) had base line PC levels below lower limit of normal were non 
survivors, 10 of 11 patients (11.8%) had base line PC levels below the lower 
limit of normal were critically ill. On other hand 29 of 85 patients (34.1%) had 
base line PC levels more than the lower limit. Twenty seven of 57 patients 
(31.8%) had base line PC more than the lower limit were survivors, 1 of 17 
patients (1.2%) had base line PC more than the lower limit was non survivor, 
and 1 of 11 patients (1.2%) had bas line PC more than the lower limit was 
critically ill. There was high statistically significant relationship between PC 
and ICU outcome  (df= 2; p= 0.001), Pearson Chi-Square were (13.547). 
 
 
Table 4.11. Correlation of protein C level with ICU outcome. 
 
Protein C level 
 Variables Categories 
Statistics ≤70 % >70 % 
Total 
 
Count 30 27 57 survivors 
 % of Total 35.3% 31.8% 67.1% 
Count 16 1 17 non survivors 
 % of Total 18.8% 1.2% 20.0% 




 % of Total 11.8% 1.2% 12.9% 
Count 56 29 85 Total 
 
 
 % of Total 65.9% 34.1% 100.0% 












4.9. Data for organ dysfunction in relation to CRP levels at ICU 
admission. 
 
4.9.1. Renal function tests in relation to CRP levels upon ICU admission  
As shown from table 4.12. there was relation between CRP levels and urea 
level, the mean of urea (37.1±18.7 mg/dL) in group 1, (61.2±28.2 mg/dL) in 
group 2, and (64.1±52.3 mg/dL) in group 3. The mean of creatinine was 
(0.9±0.5 mg/dL) in group 1 was less than the mean ingroup 2,and in group 3. 
The mean of TP level was (5.7±1.1 g/dL) in group 1 higher than the mean in 
group 2, and in group 3. The mean of ALb was (3.3±0.8 g/dL) in group 1 
higher than the mean in group 2, and in group 3. The mean of Na+ was 
(143.2±10.2 mmol/L) in group 1 there no difference in group 2,and in group 3. 
The mean of K+ was (4.0 ± 0.7 mmol/L) in group 1 that less than the mean in 
group 2,and in group 3.  The mean of Ca+2 (9.2±0.8 mmol/L) ingroup 1 was 
higher than the mean in group 2, and in group 3. 
 




(CRP 10-40 mg/dl)  
Group 3 
(CRP >40mg/dl) variable 





 Urea (mg/dL) 37.1 18.7 61.2 28.2 64.1 52.3 
Creatinine(mg/dL) 0.9 0.5 1.9 1.4 1.5 1.7 
 TP(g/dL)      5.7 1.1 4.9 1.3 5.4 1.3 
 Alb (g/dL) 3.3 0.8 2.7 0.5 2.7 0.8 
 Na+ (mmol/L) 143.2 10.2 140.8 3.4 142.5 8.4 
 K+ (mmol/L) 4.0 0.7 5.2 1.5 4.3 0.9 
 Ca+2 (mg/dL) 9.2 0.8 8.1 1.0 8.6 1.0 

















4.9.2. Hepatic function tests in relation to CRP levels upon ICU 
admission 
 
As shown in table 4.13. There were differences between the means of ALT, 
AST, TB, and DB (35.6±25.9 u/L, 38.4±25.6 u/L, 0.8±0.1mg/dL and 
0.4±0.02mg/dL) respectively in group 1 , the means in group 2 (309.9± 926.1 
u/L, 411.1± 1077.6 u/L, 1.1± 1.2 mg/dL and 0.5±0.6 mg/dL),and in group 3 








(CRP 10-40 mg/dl) 
Group 3  
(CRP >40mg/dl) variable 





  ALT (u/L) 35.6 25.9 309.9 926.1 58.1 60.9 
  AST (u/L) 38.4 25.6 411.1 1077.6 72.8 81.4 
  TB (mg/dL) 0.8 0.1 1.1 1.2 0.9 0.5 
  DB (mg/dL) 0.4 0.02 0.5 0.6 0.4 0.3 
             ALT= Alanin Aminotransferase, AST= Aspartate Aminotransferase, TB=Total 
            billirubin, DB= Direct billirubin 
 
 
4.9.3. Coagulation tests in relation to CRP levels upon ICU admission 
 
As shown in table 4.14, the mean of Hb, PT, PTT and INR levels was 
(11.4±2.1 gm/dL, 36.6±33.6 sec., 50.1±33.2 sec. and 3.6±3.4) in group 1 
higher than the means in group 2 (11.0± 2.6 gm/dL, 22.2± 6.5sec., 38.3 
±15.8sec.and 2.0± 0.8) ,and in group 3 (10.8± 1.9 gm/dL,25.2± 23.8sec.,42.1± 
27.1sec.and 2.3± 2.1). The mean of Neutrophil was (84.9±10.5 %) in group 3 
was higher than the mean in group 2 (81.41± 3.4%) and in group 1 
(81.6±12.5%). The mean of PC was (72.2±25.5%) in group 2 higher than the 
mean in group 1 (61.8±27.4%) and ( 62.3±20.9%) in group 3. The mean of 
PLT was (131.5±84.7*109/L) in group 2 was lower than the mean in group 1 
(190.3±70.1*109/L) and ( 202.1±133.9*109/L) in group 3. And the mean of 
WBC was (10.0±6.0*109/L) in group 2 lower than the mean in group 1 









(CRP 10-40 mg/dl) 
Group 3  
(CRP >40mg/dl) variable 





  WBC (109/L) 12.5 5.2 10.0 6.0 12.4 7.7 
  RBC (1012/L) 4.1 1.0 4.2 1.1 3.9 0.7 
  Hb (gm/dl) 11.4 2.1 11.0 2.6 10.8 1.9 
  PLT (109/L) 190.3 70.1 131.5 84.7 202.2 133.9 
  PT (sec.) 36.6 33.6 22.2 6.5 25.2 23.8 
  PTT( sec.) 50.1 33.2 38.3 15.8 42.1 27.1 
  INR 3.6 3.4 2.0 0.8 2.3 2.1 
  PC % 61.8 27.4 72.2 25.5 62.3 20.9 
  Neutrophil % 81.6 12.5 81.4 13.4 84.9 10.5 
              WBC= White blood cells, RBC= Red blood cells, Hb= Hemoglobin, PLT= platelets 
             count, PT= prothrombin time, PTT= partial thromboplastin time, INR= International 




4.9.4. Pulmonary function tests in relation to CRP levels upon ICU 
admission  
 
As shown in table 4.15, that was no difference between the mean of PH, 
PCO2  and fio2 in group 1 and the mean in group 2,and in group 3. There was 
difference between the mean of  HCO3 in group 1 (21.7±6.1 mEq/L), the 
mean in group 2 (25.7±14.2 mEq/L) and in group 3 (18.3±5.8mEq/L). The 
mean of SO2 and BE was (89.6±14.3%, -1.6±8.3) respectively in group 1 was 
higher than the mean in group 2 (82.8±17.1%, -1.8 ±11.4) and in group 3 
(80.1±14.7%,-6.0±10.5). There was difference between the mean of  PO2 in 
group 1(58.9±31.0mmHg) the mean in group 2 (67.5±47.8 mmHg), and in 













       Table 4.15.  Pulmonary function tests in relation to CRP levels upon ICU 




(CRP 10-40 mg/dl) 
Group 3  
(CRP >40mg/dl) variable 





PH 7.3 0.1 7.4 0.2 7.3 0.2 
PCO2 
mmHg 44.0 8.9 45.2 11.0 39.9 9.3 
HCO3 
mEq/L 21.7 6.1 25.7 14.2 18.3 5.8 
SO2 % 89.6 14.3 82.8 17.1 80.1 14.7 
FIO2 0.4 0.1 0.4 0.0 0.5 0.2 
       BE -1.6 8.3 -1.8 11.4 -6.0 10.5 
PO2 mmHg 58.9 31.0 67.5 47.8 57.3 20.2 
PCO2= partial pressure of carbon dioxide, HCO3= bicarbonate, SO2= oxygen saturation, 



























4.10. Differences between the mean of variables of organ 
dysfunction due to CRP groups. 
 
 
4.10.1. Differences between the mean of variables of renal function tests 
among CRP groups 
 
As shown in table 4.16, there were statistically significant differences between 
the means of urea, K+, and Ca+2 among CRP groups (p=0.033, 0.012, 0.025), 
respectively. On the other hand there were no statistically significant 
differences between the means of creatinin,  TP, ALb, and  Na+,  (p= 0.106, 
0.326, 0.067, 0.78)  respectively among CRP groups. 
 
 
Table 4.16.  Differences between the mean of variables of renal function tests 
among CRP groups. 
 Dependent Variable  Source Sum of Squares df Mean Square F Sig. 
Between 
Groups 12040.097 2 6020.048 
Within Groups 130211.291 77 1691.056 urea 
Total 142251.388 79  
3.560 .033 
Between 
Groups 9.126 2 4.563 
Within Groups 151.730 77 1.971 creatinin 
Total 160.856 79  
2.316 .106 
Between 
Groups 3.435 2 1.718 
Within Groups 71.851 48 1.497 
TP 
 
Total 75.286 50  
1.147 .326 
Between 
Groups 3.085 2 1.542 
Within Groups 25.952 48 .541 ALb 
Total 29.036 50  
2.853 .067 
Between 
Groups 36.303 2 18.151 
Within Groups 4010.180 55 72.912 Na+ 
Total 4046.483 57  
.249 .780 
Between 
Groups 8.702 2 4.351 
Within Groups 49.473 55 .900 K+ 
Total 58.176 57  
4.837 .012 
Between 
Groups 6.952 2 3.476 
Within Groups 38.260 44 .870 Ca
+2 
Total 45.213 46  
3.998 .025 
 








4.10.2. Differences between the mean of variables of hepatic function 
tests among CRP groups. 
 
As shown in table 4.17, there was statistically significant differences between 
the mean of AST among CRP groups (p=0.030). on the other hand there was 
no statistically significant differences between the mean of ALT, TB, and  DB 
(p= 0.071, 0.258, 0.312)  respectively among CRP groups. 
 
 
Table 4.17. Differences between the mean of variables of hepatic function tests 
among CRP groups. 
 
Dependent Variable  Source Sum of Squares df Mean Square F Sig. 
Between Groups 744999.900 2 372499.950 
Within Groups 10460647.088 77 135852.560 ALT 
Total 11205646.988 79  
2.742 .071 
Between Groups 1360653.795 2 680326.898 
Within Groups 14220954.155 77 184687.716              AST 
Total 15581607.950 79  
3.684 .030 
Between Groups .953 2 .477 
Within Groups 26.592 77 .345             TB 
Total 27.545 79  
1.380 .258 
Between Groups .209 2 .105 
Within Groups 6.817 77 .089 DB 
Total 7.026 79  
1.183 .312 
ALT= Alanin Aminotransferase, AST= Aspartate Aminotransferase, TB=Total billirubin,                                                                                                                                                                                                          

























4.10.3. Differences between the mean of variables of coagulation  tests 
among CRP groups 
 
 
As shown in table 4.18, there was no statistically significant differences 
between the mean of WBC, RBC, Hb, PLT, PT, PTT, INR, PC and neutrophil 
(p=0.502, 0.609, 0.473,0.136, 0.376,0 .615, 0.249, 0.318, 0.526, respectively) 
among CRP groups 
 
Table 4.18. Differences between the mean of variables of coagulation  tests 
among CRP groups. 
 
Dependent Variable  Source Sum of Squares df 
Mean 
Square F Sig. 
Between 
Groups 63.602 2 31.801 
Within Groups 3520.393 77 45.719  WBC (10
9/L) 
Total 3583.995 79  
.696 .502 
Between 
Groups .813 2 .406 
Within Groups 47.175 58 .813    RBC (10
12/L) 
Total 47.988 60  
.500 .609 
Between 
Groups 6.661 2 3.330 
Within Groups 339.157 77 4.405             Hb (gm/dl) 
Total 345.818 79  
.756 .473 
Between 
Groups 49954.853 2 24977.427 
Within Groups 939441.147 77 12200.534  PLT (10
9/L) 
Total 989396.000 79  
2.047 .136 
Between 
Groups 1296.671 2 648.335 
Within Groups 24565.349 38 646.457 
            PT (sec.) 
 
Total 25862.020 40  
1.003 .376 
Between 
Groups 754.543 2 377.271 
Within Groups 29066.501 38 764.908 PTT( sec.) 
Total 29821.044 40  
.493 .615 
Between 
Groups 17.053 2 8.527 
Within Groups 224.757 38 5.915              INR 
Total 241.811 40  
1.442 .249 
Between 
Groups 1364.043 2 682.021 
Within Groups 45158.157 77 586.470              PC % 
Total 46522.200 79  
1.163 .318 
Between 
Groups 179.665 2 89.832 
Within Groups 8304.188 60 138.403 Neutrophil 
Total 8483.853 62  
.649 .526 
 
WBC= White blood cells, RBC= Red blood cells, Hb= Hemoglobin, PLT= platelets count, PT= 






4.10.4. Differences between the mean of variables of pulmonary function 
tests among CRP groups 
 
 
As shown in table 4.19, there was no statistically significant differences 
between the mean of PH , PCO2, HCO3, SO2, FIO2 , BE ,and PO2 (p=0.313, 
0.508, 0.385, 0.370, 0.634, 0.593, 0.867, respectively)  due to CRP groups 
 
 
Table 4.19. Differences between the mean of variables of pulmonary function 
tests among CRP groups. 
Dependent 




Square F Sig. 
Between 
Groups .051 2 .026 
Within Groups .460 22 .021 PH 
Total .511 24  
1.225 0.313 
Between 
Groups 126.300 2 63.150 
Within Groups 1989.700 22 90.441 PCO2 
Total 2116.000 24  
0.698 0.508 
Between 
Groups 120.476 2 60.238 
Within Groups 825.524 14 58.966 HCO3 
Total 946.000 16  
1.022 0.385 
Between 
Groups 468.060 2 234.030 
Within Groups 4954.100 22 225.186 SO2 
Total 5422.160 24  
1.039 0.370 
Between 
Groups .013 2 .007 
Within Groups .067 5 .013 FIO2 
Total .080 7  
0.500 0.634 
Between 
Groups 102.346 2 51.173 
Within Groups 1808.972 19 95.209 BE 
Total 1911.318 21  
0.537 0.593 
Between 
Groups 287.633 2 143.816 
Within Groups 16983.317 17 999.019 PO2 
Total 17270.950 19  
0.144 0.867 
PCO2= partial pressure of carbon dioxide, HCO3= bicarbonate, SO2= oxygen saturation, 













4.11. Multiple comparisons due to C-reactive protein groups 
 
Table 4.20 shows the mean difference between groups among CRP groups, 
the variables that had significant difference and the groups which had the 
significant differences.The mean difference (372.7) was significant between 
group 1 and group 2 and between group 3 and group 2 (338.3) and no 
significant mean difference (34.4) between group 1 and group 3, regarding 
AST. Regarding K+, there was significant mean difference (1.2) between 
group 1 and group 2, group 2 and group 3 the difference was (0.9), no 
significant mean difference (0.3) was between group 1 and group 3. 
Regarding Ca+2, the mean difference (1.1) was significant between group 2 
and group 1, group1 and group 3 the difference was (0.6), no significant mean 
difference (0.5) was between the group 2 and group 3. Regarding Urea, the 
mean difference (24.1) was significant between group 1 and group 2, group1 
and group 3 the mean difference was (27.0), there was no significant mean 
difference (2.9) between group 2 and group 3.  
 
Table 4.20.  Multiple Comparisons among C-reactive protein groups 
(J) CRP.GRO C-reactive protein Group 1 Group 2             Group 3 Dependent 





Group 1  -372.7* -34.4 
Group 2 372.7*  338.3* AST 
            Group 3 34.4 -338.3*  
Group 1  -1.2* -0.3 
Group 2 1.2*  0.9* K+ 
            Group 3 0.3 -0.9*  
Group 1  1.1* 0.6* 
Group 2 -1.1*  -0.5 Ca+ 
            Group 3 -0.6* 0.5  
Group 1  -24.1* -27.0* 
Group 2 24.1*  -2.9 Urea 
            Group 3 27.0* 2.9  
• The mean difference is significant at the 0.05 level. 
 
Group 1=CRP<10mg/dL, group 2=CRP 10-40mg/dL,group 3=CRP>40mg/dL, AST=Asparate 








4.12. CRP levels correlation with clinical outcome 
 
Table 4.21, shows that the overall mortality rate was 20%, 47of 85 patient 
(55.3%) had baseline CRP level at group 3, 13 patient of 85 (15.3%) had 
baseline CRP level at group 2, and 25 patient of 85 (29.4%) had baseline of 
CRP level in normal limit group 1. Thirty patients of 57 (35.3%) were 
survivors, 11 patients of 17 (12.9%) they were non survivors, and 6 patients of 
11 (7.1%) were critically ill, had baseline of CRP levels  group 3. Ten patients 
of 57 (11.8%), were survivors, 2 patients of 17 (2.4%) they were non 
survivors, and 1 patient of 11 (1.2%) was critically ill, had baseline CRP levels 
at group 2. Seventeen patients of 57 (20%) were survivors, 4 patients of 17 
(4.7%) were non  survivors and 4 patients of 11 (4.7%) were critically ill, had 
baseline CRP levels group 1. 
 
76.47% of  non survivors had baseline of CRP levels more than the normal 
limit, 70.17% had baseline of CRP levels more than the normal limit, regarding 
to survivors, 63.63% of critically ill had baseline of CRP levels  more than the 
normal limit. 
As shown in table 4.21 there were no statistically significant difference 
between CRP levels and ICU outcome (P-Value= 0.856, df = 4), Pearson Chi-
Square was ( 1.3344). 
 














Count 17  10  30  57  survivors 
 % of Total 20%  11.8%  35.3%  %  67.1  
Count 4  2  11  17  non 
survivors 
 % of Total 4.7%  2.4%  12.9%  20%  





 % of Total 4.7%  1.2%  7.1%  12.9%  
Count 25  13  47  85  Total 
% of Total 29.4%  15.3%  55.3%  100% 




4.13. Relationship between protein C levels and length of stay 
among patients admitted to ICU. 
 
It was found that there were no statistically significant correlations between 
protein C with either length of stay ( r= -0.093 ,  p = 0.396) or length of stay 
among survivors patients (r= -0.149 , p= 0.269) as shown in Fig.4.3 and 







































          Figure.4.4. Correlation between protein C and length of stay at admission ICU 




4.14.  Relationship between protein C levels and platelets 
counts among patients admitted to ICU. 
 
There was no significant correlations between protein C with platelets count 


















Figure. 4.5. Correlation between protein C levels and platelets count  
 
 
4.15.  Coagulation markers correlation with ICU outcome  
 
Table 4.22, shows that the levels of platelets, PT and PTT were not 
significantly associated with ICU outcome (p=0.373, p=0.864 and  
p=0.621respectively). But the levels of PC  were significantly associated with 
ICU outcome (p=0.006). 
  
 
Table 4.22. Correlation of coagulation markers with ICU outcome 
ICU outcome 

















0.373 143.55 ± 89.69 177.88 ± 168.04 193.93 ± 90.99 
PLT 
0.864 27.78 ± 27.47 30.70 ± 28.68 25.74 ± 22.88 
PT  
0.621 38.14 ± 25.32 49.19 ± 24.93 41.93 ± 29.78 
PTT 
0.006 53.45 ± 26.73 50.47± 14.32 68.68 ± 23.61 
P. C 
PLT= platelets, PT=pothrombin time, PTT=partial thromboplastin time, PC=protein C 
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4.16. Correlation of coagulation markers with protein C  
The correlation between the coagulation markers and PC levels was weak or 
nonexistent (table 4.23). There was no significant positive correlation 
observed between the platelet levels and PC levels (p=0.123), no significant 
negative correlation observed between the PT and PC levels (p=0.309) and 
no significant negative correlation observed between PTT and PC levels 
(p=0.117). 
Table 4.23. Correlation of coagulation markers with protein C  
Protein C 
Variable 
Person correlation p-value 
PLT 0.168 0.123 
PT -0.161 0.309 
PTT -0.246 0.117 
PLT= platelets, PT=pothrombin time, PTT=partial thromboplastin time  
 
Table 4.24. displays baseline characteristics and results of the coagulation 
marker levels as one unit (ie, PT,PTT, and PLT ) of two  subgroup of patients 
selected from the ICU (normal PT,PTT,PLT, abnormal PT,PTT,PLT). There 
were statistically significant (p= 0.025) differences between the two groups 
with respect to PC. There was also little correlation among PT, PTT, and PLT 
levels and PC levels especially in the subgroup of patient that had normal PT, 
PTT, and PLT levels, the mean of PC levels in this subgroup was 79.86. A 
total 2 of 7 patients in this subgroup had PC levels below the lower limit of 
normal. 
 
Table 4.24. Characteristics of coagulation marker levels among two groups of 
patients 
Variable Group n Mean Std. Deviation 
T -test P -value 
Normal( PT,PTT,PLT)* 7 79.86 31.28 Protein C 
Abnormal(PT,PTT,PLT)* 5 38.40 18.78 
2.624 0.025 
* Three parameters altogether 




Chapter V                                                                  Discussion 
 
APC is a serine protease that inhibits coagulation factors Va and VIIIa, 
subsequently blocking the generation of thrombin. Both PAI-1 and TAFI are 
inhibitors of the endogenous fibrinolytic system. TAFI is activated by thrombin. 
APC also exhibits profibrinolytic activity by neutralizing PAI-1 or by limiting the 
activation of TAFI by limiting thrombin generation (117,118). PC circulates 
largely in the zymogen form in plasma and is activated via the complexing of 
thrombin with the endothelial cell surface protein thrombomodulin (48). In 
large blood vessels, the activation of PC to APC is facilitated by the EPCR in 
complex with thrombin-TM (119,120).   
In this study, we measured and analyzed (PC,  PT, APTT, liver function tests, 
renal function tests, pulmonary tests, CBC and CRP test) in a randomly 
selected group of patients (n = 85) from the ICU at Al- Shifa hospital (57 male, 
28 female). A total of 56 patients (65.9%) had PC levels at baseline below the 
lower limit of normal.  
Age and sex matched healthy control group were also included in the study. 
 
5.1. Relationship between protein C with gender among patients and 
controls. 
Data showed that there were no statistically significant differences between 
males and females with regard to PC levels in patients and controls groups, 
which means that gender has no effect on the concentration of PC. These 
results are congruent with others  who did not find any statistically significant 
differences  in PC levels , between males and females (113). This result may 
be explained by the fact that PC is required for both sexes as they have the 







5.2. Levels of glucose, renal, hepatic, CBC parameters, protein C and C-
reactive protein tests  among patients and controls 
The study showed statistically significant differences between patient and 
control groups with regard to glucose, urea, creatinine, AST, ALT, total bilirubin, 
direct bilirubin, WBC, neutrophil and CRP  where their mean values were higher 
in patients than controls. In contrast, serum  total protein, albumin, calcium, 
RBC, HGB, PLT and  PC mean values were lower in patients. This finding 
coincide with the conditions of patients as they had serious health problems.   
 
5.3  Values of protein C upon admission to ICU. 
The main finding of our study is that PC concentrations were generally low in 
patients admitted to the ICU, irrespective of sex, and primary diagnosis. PC 
concentrations correlated to the organ dysfunction and were associated with a 
higher risk of ICU mortality. This result is in agreement with the study 
conducted by Frank Brunkhorst and his colleagues (113). 
Low PC concentrations have been reported frequently in ICU patients. 
Previous observations (30, 99,112,121,122), however, have focused mainly 
on patients with sepsis syndromes, especially those with severe sepsis. The 
reason for the early decrease in PC concentrations is probably multifactorial. 
Acute inflammation _as a response to severe infection or trauma_ results in 
systemic activation of the coagulation system (123,124). Cytokines have been 
shown to play an important mediatory role through activation of the tissue 
factor-factor VIIa (extrinsic) pathway (125,126). Vascular endothelial cells also 
play a central role in the mechanisms that contribute to inflammation-induced 
activation of the coagulation system. Therefore, the subsequent consumption 
of anticoagulation factors, including PC, is one possible reason for the 
decreased PC levels seen in ICU patients (123). Impairment of hepatic protein 
synthesis may also be a contributing factor, due to associated hepatic 
dysfunction or substrate deficiency. 
In our study, PC concentrations decreased significantly regardless of the 
primary diagnosis. However, the minimum PC concentration was observed in 
RTA patients, ARF and COPD than other patients groups. This may not be 
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surprising, because the high degree of inflammatory reaction in those patients 
is expected to be associated with the magnitude of tissue damage. Our finding 
is in agreement with other related studies (113). 
 
5.4 Intensive care unit length of stay, and protein C concentrations 
according to primary diagnosis, gender, age and ICU outcome.  
 
The study showed that the highest number of our study group of patients were 
those who had explosive injury, that  makes our study different from  others. 
The lower the PC levels, the more was the LOS which required more 
extracorporeal support.  Median of LOS in male was higher than in female 
(table 5.1), and the mean of PC levels was lower in non survivors than in 
survivors. The mean of PC in male was lower than in female. This result is 
supported by another study (113). On the other hand our study showed that 
the median of LOS in non survivors was lower than that in survivors (table 
5.1), a result which is not in agreement with others (113).  
 
Table 5.1 ICU length of stay 
variable ICU length of stay 
(LOS)* 
Male 3 (1-5) 
Female 1 (1-3) 
Survivors 2 (1-4) 
Non survivors 1 (1-5) 
                   *LOS is presented as median (interquartile range) 
 
The ongoing conditions in our area are completely different from other areas 
in the world. We are subjected to continuous aggression and many people 
suffer injuries due to Jet-bombardment. In many situations ICU is faced with 
large numbers of injuries beyond its capacity to absorb them. ICU is forced to 
rearrange its priorities in dealing with such injuries. Some times injured 
patients are not able to get access to the hospital in the proper time which 
may be reflected on their outcome. In  our study the mean of PC was 
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(68.68±23.6%) survivors patients, (50.47±14.3%) in non survivors patients. 
but in other study the mean of PC was (76.3±28.8%) for survivors patients 
and (66.5±36.8%) in non survivors patients (113). This may be explained by 
the fact that our patients reach the ICU after a relatively long time of injury. 
Our observation concerning was increased mortality if the baseline of PC 
levels were ≤70%. These results are consistent with previous studies that 
showed decreases in PC levels which precede overt clinical symptoms 
(121,127,128), and may be predictive of potential mortality (121,127-130). 
Hence, future investigations should focus on measuring PC levels as soon as 
possible after sepsis is suspected and it should be evaluated subsequently. 
This could potentially provide a more rapid and accurate assessment of the 
patient's status. If such studies confirm that rapid declines in PC levels can be 
readily detected, and preceding clinical deterioration, this information could be 
used to guide therapy. 
5.5 ICU mortality  
Our study showed that the overall ICU mortality rate was 20%. It is higher 
than another study from Germany that showed overall ICU mortality of 14.7% 
(113). This finding could be explained on the basis of the conditions that our 
society is faced with, especially the ongoing conflict and war in Gaza strip. 
5.6 Correlation of coagulation markers with protein C 
In this study, we measured and analyzed four haemostatic markers (PC,  PT, 
PTT, and PLT) in selected patients (n=85) from ICU. A total of 56 (65.9%) 
patients studied in this work had PC levels  at baseline below the lower limit of 
normal. No significant correlation was found between PC and (PT, PTT, and 
PLT) at baseline. This result is in agreement with a study which  showed no 




5.7 Characteristics of coagulation marker levels among two groups of 
patients 
It is also interesting to point out that in this study, 2 of the 7 patients in the 
subgroup who had normal baseline values for PT, PTT, and PLT (altogether) 
had baseline PC levels below the lower limit of normal. This data suggests 
that PC may be an earlier and more sensitive marker than the more global 
coagulation markers of PT, PTT, and PLT that are currently more widely used 
in hospitals. The data from this study was supported by another study (131). 
5.8 Protein C levels and ICU outcome 
In our study we found that there was highly significant correlation between the 
survivors and non survivors patients regarding PC. However, another study 
showed no correlation at admission, but at 44-hours there was significant 
correlation (131). This difference may be related the difference between our  
patients and  theirs as well as the time of admission to ICU which may be late 
in our hospital. The same study showed that there was statistically significant 
correlation between  survivors and non survivors patients regarding to 
platelets counts at admission, but in our study there was no correlation. 
Our study showed that a group of critically ill patients were transformed to 
other advanced hospitals in other countries as they needed more 
sophisticated instruments and facilities  which are not found in our hospitals.  
Among the homeostatic markers investigated in this study, PC levels 
correlated best with the outcome of ICU patients (ie, survivors, non survivors 
and critically ill). 
5.9 Acute renal failure in patients admitted to ICU, incidence, LOS, and 
outcome  
  
Acute renal failure had an incidence of 5.9% in patients admitted to ICU, 
mortality was higher in this group. Such finding was supported by another 
study in which they found the same results. The increasing mortality in 
patients who developed ARF could be explained by the fact that those 
patients were treated with renal replacement therapy [RRT] (72.7% mortality 
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in patients treated by RRT versus 10.0% in ARF patients without need for 
RRT; P = 0.001) (107). Our data indicated we found that the length of stay in 
the ICU was lower for patients with ARF; this result is not in agreement with 
others who found  the reverse (148). These difference may be attributed to 
differences in the ICU regimens applied and lateness of admission ARF 
patients to AL-Shifa ICU.  
 
5.10 Correlation of C-reactive protein levels with mortality and organ 
failure in ICU patients 
 
C-reactive protein is a marker of inflammation that has been used to monitor 
the course of infection and inflammatory diseases (132-137). Recently, CRP 
has been seen not only as a biochemical marker of inflammation but also as 
an active modulator of the inflammatory response. In this context, we 
evaluated the correlation of CRP levels with organ failure and mortality early 
after ICU admission in a heterogeneous group of ICU patients. We found that 
increased CRP concentrations were associated with organ failure and higher 
mortality rates. C-reactive protein concentrations > 40 mg/dL upon ICU 
admission were associated with a particularly high mortality. This result was in 
agreement with others (28). Increasing or persistently high levels of CRP 
suggesting ongoing inflammatory activity and indicated a poor prognosis, 
while declining values suggesting a diminishing inflammatory reaction, which 
is associated with a more favorable prognosis. Hence, trends in CRP 
concentrations during the first 24 hr of ICU admission can be important in 
helping to decide whether or not further, invasive, diagnostic procedures are 
needed and whether therapeutic interventions should be maintained or 
modified. 
 
C-reactive protein is predominantly produced and secreted by hepatocytes, 
although other cells including alveolar macrophages may also synthesize 
CRP (138). C-reactive protein is thought to represent a measure of cytokine-
induced protein synthesis. Due to the fast rise in CRP concentrations, critically 
ill patients will often already have raised CRP levels on ICU admission. The 
relatively short half-life of approximately 19 hr makes it a useful monitor for 
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follow-up of inflammatory response, infection, and antibiotic treatment. In 
addition, laboratory tests for CRP are easily available and less costly than 
cytokine tests. 
 
Previous reports have reported CRP levels to be a prognostic index in 
different entities, including ischemic stroke (139,140), acute pancreatitis 
(141,142), nephropathy (143), terminal renal failure (144-146), and 
cardiovascular diseases (147-150). Bonig and his colleagues reported that 
CRP levels > 10 mg/dL were predictive of poor outcome after hematopoietic 
stem cell transplantation in children (151). Chronic inflammation plays a role in 
the pathogenesis of cardiovascular diseases and elevated serum levels of 
CRP are associated with an increased risk of myocardial infarction and 
sudden cardiac death in apparently healthy subjects (152). It was reported 
that high CRP levels in hemodialysis patients were closely related to high 
levels of vascular atherogenic risk factors and cardiovascular deaths (144).  
 
Serum concentrations of CRP and IL-6 have been shown to be inversely 
related to renal function in the predialytic phase of renal failure (153). In one 
study, high CRP levels at ICU admission were associated with more days of 
receiving extracorporeal support (28). But in our study we found that high 
levels of CRP at ICU admission were associated with less days at ICU. Our 
results coincide with others as ICU in all hospitals are dealing with patients 













Chapter VI                     Conclusions and Recommendations 
6.1 Conclusions 
Our study demonstrates that PC concentrations are generally low in ICU 
patients. PC levels were associated with organ dysfunction/failure and were 
independently associated with a higher risk of ICU mortality. These findings 
suggest that targeting the PC pathway may improve outcomes in patients with 
multi-organ failure of non septic origin.  
The study demonstrated an important link between low PC levels and patients 
with failing organs and those at risk of dying. 
The study confirmed that baseline PC levels are dependent predictor of 
outcome in ICU patients. 
Lower PC levels were common in ICU patients and were associated with 
several severely negative clinical outcomes, including increased mortality. 
These findings suggest that PC levels can be used prognostically and that 
such agents as PC, or preferrably, activated PC, may reverse the acquired PC 
deficiency and improve outcome.  
Recombinant PC may be a new target for therapy for patients with non – 
infectious-induced organ failure/dysfunction in the ICU. 
Abnormal three coagulation markers together (PT, PTT, PLT) coincide with 
low levels of PC. 
This is to the best of our knowledge the first study that evaluates risk factors 
for the development of ARF in a subgroup of ICU patients; additionally, the 
incidence of ARF in this patient population are described.  
C-reactive protein levels were good early marker of morbidity and mortality in 
our patients. In addition, CRP concentrations may be a valuable addition to 
predict the risk of death. Yet there were more deaths in the group with higher 
CRP levels than in the other two groups who had CRP levels <40 mg/dL. 
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6.2 Recommendations 
Introduction of PC testing as a routine in ICU at admission and consequently. 
Treatment with recombinant PC could offer a new way of interrupting the 
progression to sepsis and organ failure in high risk patients.  
Serial measurements of CRP concentrations in critically ill patients may help 
to identify patients who may require more aggressive diagnostic and 
therapeutic interventions to avoid complications. CRP concentrations may 
also be helpful in clinical trials, to identify high-risk patients who would benefit 
from new therapeutic interventions. 
 
Further research is needed dealing with large number of cases with emphasis 
on PC levels, CRP and coagulation markers. 
 
Clinical trials are proposed to evaluate the role of recombinant PC in 
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